



Project No. TREN-05-FP6TR-S07.61320-518404-DRUID

DRUID

Driving under the Influence of Drugs, Alcohol and Medicines

Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport

6th Framework Programme

Deliverable 4.4.1

Classification of medicinal drugs and driving: Co-ordination and synthesis report.

Due date of deliverable: 21.07.2011

Actual submission date: 21.07.2011

Revision date: 21.07.2011

Start date of project: 15.10.2006 Duration: 48 months

Organisation name of lead contractor for this deliverable: UVA

Revision 0.0

Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006)		
Dissemination Level		
PU	Public	
PP	Restricted to other programme participants (including the Commission Services)	x
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	

Classification of medicinal drugs and driving: Co-ordination and synthesis report.

Authors

Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain)

Partners

- Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands)
- Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium)
- Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France)
- Katerina Toulidou (CERT-HIT, Centre for Research and Technology Hellas, Greece)
- Michael Heiβing (BASt, Bundesanstalt für Straßenwesen, Germany).

Task 7.3 leader: F. Javier Alvarez (UVa, Spain)

Work Package Leader: F. Javier Alvarez (UVa, Spain)

Project Co-ordinator: Horst Schulze (BASt, Germany)

Project Funded by the European Commission under the Transport RTD Programme of the 6th Framework Program

Table of contents

	page
List of Abbreviations	4
Executive Summary D.4.1.1	5
Review of existing classification efforts.	
Executive Summary D.4.2.1	7
The establishment of criteria for a European categorization, based on expert consensus.	
Executive Summary D.4.3.1	9
Establishment of framework for classification/categorisation and labelling of medicinal drugs and driving.	
DRUID WP4 categorization/labelling and patient-oriented information on medicines and driving: Alphabetical list	12

List of Abbreviations

ATC: Anatomical Therapeutic Chemical classification system

DRUID: Driving Under the Influence of Drugs, Alcohol and Medicines

EU: European Union

ICADTS: International Council on Alcohol, Drugs and Traffic Safety

PIL: Patient Information Leaflet

SmPC: Summary of Product Characteristics

WP: Work Package

DG Sanco: Directorate General for Health & Consumers (SANCO)

DG Move: European Commission Mobility & Transport

Executive Summary D.4.1.1

Review of existing classification efforts.

In total, 16 systems were found (table 9). Some of these systems are no true categorization systems: Germany directly reproduced ratings from Wolschrijn, and 5 systems have not defined categories (Greece, the Netherlands, Norway, Denmark and Finland). Only one true categorization system also included warning labels (France II).

Clear relations can be seen between the different systems (figure 3). In this way, all categorizations (except Portugal) are linked to Wolschrijn. When looking at the structure of the systems, the largest evolution has been the number (and descriptions) of categories. The list by Wolschrijn included 7 categories. At first, the categories were copied (Belgium), but later on the categories were summarized and only three categories remained (Spain I). The most recent and extensive lists (France II and ICADTS) have maintained these three categories, but have added practical guidelines for patient and doctor. One list (ICADTS) introduced a calibration to BAC levels.

Table 1: Comparison of classification and labeling systems

	# medicinal drugs	Classification	# categories	Warning label	Legal
Wolschrijn	572	X	7		
Germany	406		Scale values		
Belgium	182	X	7		
Spain I (DGT/UVa)	363	X	3		
Spain II (semFYC/UVa)	395	X	4		
Spain				X	
France I (CERMT)	508	X	4		
France II (official)	311	X	3	X	X
ICADTS	389	X	3		
Portugal	241	X	5		
Greece I (legal)	89		NA		X
Greece II (monographs)	92		NA		
The Netherlands	156		NA	X	
Norway	87		NA	X	
Denmark	83		NA	X	
Finland	68		NA	X	




Figure 1: Relations between the different classification and labeling systems

Executive Summary D.4.2.1

The establishment of criteria for a European categorization, based on expert consensus.

The aim of this deliverable is to develop and agree on input for the establishment of a European categorisation system for medicines and driving. After a short review of the most significant existing developments of categorisation systems in Europe, a critical discussion has been presented to explain the need for such a categorisation system. It is clear that such a system will serve most of the needs of health care professionals, drug regulatory agencies, drug manufacturers and patients. For patients to make the best (and safest) use of their medicines, clear warnings and symbols are needed. Developments in France show clearly that a multi-level categorisation system is better in showing difference between the least and most impairing medicine within one therapeutic class and that warning labels are needed to guide patients in deciding about the use while taken the medicine.

For the development of input for a European categorisation system it has been decided to address the Pharmacovigilance Working Party of the Committee for Medicinal Products for Human Use (CHPM). Together with WP 4 Partners three small-scale invitational workshops have been organised in 2008 in which representatives of regulatory agencies in 9 Member States participated. Based on their discussions a first step to harmonize the categorisation system could be achieved: the adoption of the Guidelines for the Summary of Product Characteristics in September 2009 (which applied as from 1st of May 2010), in which categories a) no or negligible influence, b) minor, c) moderate influence, and d) major influence on driving fitness are specified with some important guidance in special circumstances.

In describing the various categories, discussions among WP 4 partners clearly showed that emphasis should be given to the evaluation of the active substances in order to increase the feasibility of such a system. In order to categorise a medicine with regard to driving, several steps are identified using data from different sources: pharmacodynamic and pharmacokinetic data; pharmaco-vigilance data, experimental and epidemiological data and additional data (e.g. from accidentology). In addition, for each category information for developing directions for health care professionals and warning levels and warning symbols could be presented.

In the last two years (2010 and 2011) of Task 4.2 progress and steps forward based on the input from WP4 partners have been discussed with the Pharmacovigilance Working Party, resulting in consensus development based on a compromise. Currently national approaches differ substantially: from France at one end of the extreme (with three-level pictogram labelling) to Sweden at the other end where the existing pictogram was replaced with a generic warning in the patient leaflet. As a consequence the consensus was reached that a basic 2 level framework would be developed as the basis for warnings to the patient in the Patient Information Leaflet. For medicines without a potential relevant influence on driving (no or negligible, or minor influence) and for medicines with a potential relevant influence on driving (moderate influence, or major influence) the wording has been proposed.

This consensus on the wording in the Patient Information Leaflet is another and important step to harmonize information to patients on a medicine's impairing effects on fitness to drive. However, it is acknowledged by the Pharmaco-vigilance Working Party and WP4 partners that at the Member States' level more activities are needed in order to reinforce the awareness of patients on the effects of medicines on fitness to drive, e.g. by the use of an alerting pictogram on the product packaging or further stratification of the number of categories of risk with a maximum of four.

In the recommendations of this Deliverable emphasis is given to improve information related to effects on driving in the Patient Information Leaflet by simple and patient-centred directions. The 2 level systems for the Patient Information Leaflet should be further based on clarifying the criteria for the evidence in forming the categories. Therefore collaborative efforts by DRUID experts, and the members of the Pharmaco-vigilance Working Party, among other bodies, preferably with support of EU bodies, such as DG Sanco and DG Move, are recommended. Finally it is recommended, that the development of supplementary information for patients (e.g. warning levels and pictograms) and health care professionals (e.g. prescribing and dispensing guidelines) should be guided with input provided by DRUID results (D4.2.1, D 4.3.1, D 7.3.2 and D 7.4.2.) as well as experience in EU Member States.

Executive Summary D.4.3.1

Establishment of framework for classification/categorisation and labelling of medicinal drugs and driving.

The establishment of criteria for a European categorisation will have to serve most of the needs of all parties involved: health professionals, drug regulatory agencies, drug manufacturers and patients. Clear warnings and symbols are needed so patients use their medicines in the most optimal (and safest) way possible

The DRUID WP4 expert group established and agreed that, according to its influence on the ability to drive, a medicine could, regarding to driving, be categorized as followed:

- category 0 (no or negligible influence on fitness to drive),
- category I (minor influence on fitness to drive),
- category II (moderate influence on fitness to drive),
- and category III (severe influence on fitness to drive).

The DRUID methodology on categorization/labelling on medicines and driving.

In summary, categorisation of a medicine on driving includes several steps of evaluation after taken into account the conditions of use of the medicine on the European Union market:

1. Pharmacodynamic and pharmacokinetic data
2. Pharmacovigilance data (including prevalence of unwanted effects reported in the SmPC)
3. Experimental and epidemiological data
4. Additional data derived from the Patient Information Leaflet (PIL) and existing categorization systems
5. Synthesis

Basically conditions of use of the medicine, pharmacodynamics, pharmacokinetic data, and pharmacovigilance data (including prevalence of unwanted effects) were derived from the SmPC, while section 3 was based on a scientific literature search. Additional data step consisted of reviewing section 4.7 of the SmPC “Effects on ability to drive and use machines” and the PIL section on “driving and using machines” as well as reviewing the previous categorizations (if available) of the medicine in Belgium, France, Spain as well as to the ICADTS list.

After evaluating all the available data, a provisional category was assigned to each active substance. The provisional category was proposed and discussed during WP4 meetings where a final and definitive category was assigned and approved by all WP4 partners.

A mechanism for modifying the classification, based on new evidence.

The existing methodology on DRUID categorization on medicines and driving, allows to, if new evidences emerges, re-categorise the medicine or confirm the previous categorisation following again the same 5 step process.

Classification/categorization, labelling and patient oriented information for the relevant therapeutic groups of medicines available in the European Union market.

The aim of WP4 was to provide a categorization for the relevant therapeutic groups of medicines available on the European Union Market.

In this way, DRUID task 4.3 was able to provide categorization, labelling and patient-oriented information for the following ATC groups (The Anatomical Therapeutic Chemical –ATC– classification system; <http://www.whocc.no/>).

Individual medicines were categorized according to the DRUID classification system.

- A - ALIMENTARY TRACT AND METABOLISM
- B - BLOOD AND BLOOD FORMING ORGANS
- C - CARDIOVASCULAR SYSTEM
- D - DERMATOLOGICALS
- M - MUSCULO-SKELETAL SYSTEM
- N - NERVOUS SYSTEM
 - N01 ANAESTHETICS
 - N02 ANALGESICS
 - N03 ANTIEPILEPTICS
 - N04 ANTIPARKINSON
 - N05 PSYCHOLEPTICS
 - N05A Antipsychotics
 - N05B Anxiolytics
 - N05C Hypnotics and sedatives
 - N06 PSYCHOANALEPTICS
 - N06A Antidepressant
 - N06B Psychostimulants, agents used for ADHD (Attention Deficit and Hyperactivity Disorder) and Nootropics
 - N06C Psycholeptics and psychoanaleptics in combination
 - N06D Anti-dementia drugs
 - N07 OTHER NERVOUS SYSTEM DRUGS
- R - RESPIRATORY SYSTEM
- S - SENSORY ORGANS

Furthermore, Fact Sheets were produced for the N01-N07 (nervous system) and R06 (respiratory system - antihistamines) ATC groups of medicines. Each fact sheet contains information on: source of information, presentations, indications, posology and method of administration, pharmacodynamic and pharmacokinetic properties, possible side-effects related to driving, Summary of Product Characteristics (SmPC) section 4.7 effects on ability to drive and use machines, leaflet section on driving and using machines, studies on psychomotor performance and risk studies, current categorization in some EU countries, proposed DRUID categorization, information for the patient, and place and date of agreement by the DRUID WP4 members.

For analysis and categorisation The DRUID project has proposed a total of 3,054 medicines from these ATC groups. Of these 3,054 medicines, 1,513 have not been categorized, because they are not available on the European Union market (not available on DRUID WP4 countries Belgium, France, Greece, Germany, Netherlands, and Spain, as well as in the UK and Ireland), as there is no sense in categorizing/labelling medicines which are not available.

The distribution of the 1,541 categorized medicines was as follows: Category 0 – 50,3%, Category I – 26%, Category II – 11,2%, Category III – 5,8%, Multiple category – 4,4% and the Depending on the medicine in combination 2,3%.

Multiple categories: This appeared when a medicine can be included in more than one category. There can be several reasons for this: In most cases, the different categorization DRUID 6th Framework Programme

depended on the route of administration (topical, oral, parenteral, etc). In the case of some medicines, in special ophthalmological preparations (S01), the different categorization depended on the presentation form of the medication (aqueous-vehicle, cream, drops or ointment, etc.), which is related with the duration of its action. In one case, codeine, categorization was based on the dose of codeine base administered. For two hypnotics, zolpidem and zaleplon, categorization was based on the time after the medication was taken.

Depending on medicines in combination: This was stated when the categorization depended on another medicine combined with the one under evaluation.

DRUID WP4 categorization/labelling and patient-oriented information on medicines and driving: Alphabetical list

A	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
2-(4-chlorphenoxy)-ethanol	D01AE06	NE	NE
Abciximab	B01AC13	0	<ul style="list-style-type: none"> • No special advice
Absorbable gelatine sponge	B02BC01	0	<ul style="list-style-type: none"> • No special advice
Acadesine	C01EB13	NE	NE
Acamprosate	N07BB03	0	<ul style="list-style-type: none"> • The treatment has to be used according to the recommended dose. • Alcohol cessation can also cause behavioural changes and requires follow-up and counselling. • Driving with this treatment should require an approval by driving licence administration.
Acarbose	A10BF01	0	<ul style="list-style-type: none"> • No special advice
Acebutolol	C07AB04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Acebutolol and thiazides	C07BB04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Aceclidine	S01EB08	NE	NE
Aceclidine, combinations	S01EB58	NE	NE
Aceclofenac	M01AB16	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the

			treatment.
Aceclofenac	M02AA25	0	• No special advice
Acefylline piperazine	R03DA09	NE	NE
Acemetacin	M01AB11	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
		0	• No special advice
Acepromazine	N05AA04	NE	NE
Acetarsol	A07AX02	NE	NE
Acetazolamide	S01EC01	II	<ul style="list-style-type: none"> • Inform the patient that this ocular medication causes drowsiness, fatigue and transient myopia which may impair the ability to drive or operate machinery. • Advise the patients to exercise caution in night driving and other hazardous occupations in conditions of poor illumination.
Acetic acid	S02AA10	NE	NE
Acetohexamide	A10BB31	NE	NE
Acetophenazine	N05AB07	NE	NE
Acetoxolone	A02BX09	NE	NE
Acetylcarnitine	N06BX12	NE	NE
Acetylcarnitine	N06BX12	NE	NE
Acetylcholine	S01EB09	II	<ul style="list-style-type: none"> • Inform the patient that this ocular medication causes miosis which usually results in difficulties for his/her sight to adapt to the dark. • Advise the patients to exercise caution in night driving and other hazardous occupations in conditions of poor illumination
Acetylcysteine	R05CB01 S01XA08	0	• No special advice
Acetyldigitoxin	C01AA01	NE	NE
Acetyldigoxin	C01AA02	NE	NE
Acetyldigoxin, combinations	C01AA52	NE	NE
Acetyldihydrocodeine	R05DA12	II	• Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (drowsiness, sedation)

			<ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Acetylglycinamide chloralhydrate	N05CC03	NE	NE
Acetylic acid and corticosteroids	M01BA03	NE	NE
Acetylleucine	N07CA04	NE	NE
Acetylsalicylic acid	A01AD05 B01AC06 N02BA01	0	<ul style="list-style-type: none"> • No special advice
Acetylsalicylic acid, combinations excl psycholeptics	N02BA51	NE	NE
Acetylsalicylic acid, combinations with psycholeptics	N02BA71	NE	NE
Aceexamato de zinc	A02BX	0	<ul style="list-style-type: none"> • No special advice
Aciclovir	D06BB03	0	<ul style="list-style-type: none"> • No special advice
Aciclovir	S01AD03	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery
Aciclovir, combinations	D06BB53	NE	
Acipimox	C10AD06	0	<ul style="list-style-type: none"> • No special advice
Acitretin	D05BB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (blurred or decreased night vision) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Acriflavinium chloride	R02AA13	NE	

Acrivastine	R06AX18	I	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, insomnia) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Adapalene	D10AD03	0	<ul style="list-style-type: none"> • No special advice
Adapalene, combinations	D10AD53	0	<ul style="list-style-type: none"> • No special advice
Ademetionine	A16AA02	NE	
Adenosine	C01EB10	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Adinazolam	N05BA07	NE	NE
Adrafinil	N06BX17	NE	NE
Adrafinil	N06BX17	NE	NE
Adrenalone	A01AD06	NE	NE
Adrenalone	B02BC05	NE	NE
Agalsidase alfa	A16AB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Agalsidase beta	A16AB04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Agomelatine	N06AX22	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next

			<p>visit and to be careful in other situations, as well (e.g. operating machinery and working at heights).</p> <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Ajmaline	C01BA05	NE	
Alanyl glutamine	B05XB02	NE	
Alaproclate	N06AB07	NE	
Albumin	B05AA01	0	<ul style="list-style-type: none"> • No special advice
Albumin tannate	A07XA01	NE	
Albumin tannate, combinations	A07XA51	NE	
Alclofenac	M01AB06	NE	
Alclometasone	D07AB10	0	<ul style="list-style-type: none"> • No special advice
Alclometasone	S01BA10	NE	
Alcuronium	M03AA01	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Alendronic acid	M05BA04	0	<ul style="list-style-type: none"> • No special advice
Alendronic acid and colecalciferol	M05BB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. headache, dizziness, and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Alfa1 antitrypsin	B02AB02	0	<ul style="list-style-type: none"> • No special advice
Alfacalcidol	A11CC03	0	<ul style="list-style-type: none"> • No special advice
Alfaxalone	N01AX05	NE	
Alfentanil	N01AH02	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using

			<p>machinery and working at heights)</p> <ul style="list-style-type: none"> • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Algedrate	A02AB02	0	<ul style="list-style-type: none"> • No special advice
Alginic acid	A02BX13	NE	
Alglucerase	A16AB01	NE	
Alglucosidase alfa	A16AB07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Alimemazine	R06AD01	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred vision, tremor and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Alipogene tiparvovec	C10AX10	NE	
Aliskiren	C09XA02	0	<ul style="list-style-type: none"> • No special advice
Aliskiren and hydrochlorothiazide	C09XA52	0	<ul style="list-style-type: none"> • No special advice.
Alitretinoin - Oral administration - Topical use	D11AX19	I 0	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (blurred or decreased night vision) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Alizapride	A03FA05	NE	
Allobarbital	N05CA21	NE	
Allopurinol	M04AA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. somnolence, dizziness vertigo or ataxia), and not to

			drive as long as side-effects persist. <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Allopurinol, combinations	M04AA51	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. somnolence, dizziness vertigo or ataxia), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Almagate	A02AD03	0	<ul style="list-style-type: none"> • No special advice
Almasilate	A02AD05	0	<ul style="list-style-type: none"> • No special advice
Alminoprofen	M01AE16	NE	
Almitrine	R07AB07	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Almotriptan	N02CC05	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Alogliptin	A10BH04	NE	
Aloglutamol	A02AB06	0	<ul style="list-style-type: none"> • No special advice
Alosetron	A03AE01	NE	
Aloxiprin	B01AC15 N02BA02	NE	

Alprazolam	N05BA12	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days. Advise your patient not to drive then.
Alprenolol	C07AA01	I	<ul style="list-style-type: none"> • No special advice
Alprostadil	C01EA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Alteplase	B01AD02	0	<ul style="list-style-type: none"> • No special advice
Alteplase	S01XA13	NE	
Althea root	R05CA05	NE	
Altizide and potassium-sparing agents (spironolactone)	C03EA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Alum	S01XA07	NE	
Aluminium acetoacetate	A02AB05	0	<ul style="list-style-type: none"> • No special advice
Aluminium acetotartrate	S02AA04	NE	
Aluminium chloride	D10AX01	0	<ul style="list-style-type: none"> • No special advice
Aluminium chlorohydrate	D09AA08 M05BX02	NE	
Aluminium clofibrate	C10AB03	NE	
Aluminium glycinate	A02AB07	0	<ul style="list-style-type: none"> • No special advice
Aluminium hydroxide	A02AB01	0	<ul style="list-style-type: none"> • No special advice

Aluminium nicotinate	C10AD04	NE	
Aluminium oxide	D10AX04	NE	
Aluminium phosphate	A02AB03	0	• No special advice
Aluminium preparations	C05AX01	0	• No special advice
Alverine	A03AX08	0	• No special advice
Alverine, combinations	A03AX58	NE	
Alvimopan	A06AH02	NE	
Amantadine	N04BB01	I	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Some central nervous system unwanted effects (like confusion) are more common when amantadine is administered concurrently with anticholinergic agents.
Ambazone	R02AA01	NE	
Amibenonium	N07AA30	NE	
Ambrisentan	C02KX02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ambroxol	R05CB06	0	• No special advice
Ambutonium and psycholeptics	A03CA07	NE	
Amcinonide	D07AC11	NE	
Amfepramone	A08AA03	NE	
Amfetamine	N06BA01	NE	
Amfetamine	N06BA01	NE	
Amifampridine	N07XX05	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • The treatment has to be used according to the recommended dose. • Vertigo and hearing loss requiring this treatment can also impair ability to drive.
Amikacin	D06AX12	0	• No special advice
Amikacin	S01AA21	NE	
Amiloride	C03DB01	0	• No special advice.
Amineptine	N06AA19	NE	

Amino (diphenylhydantoin) valeric acid	N03AB03	NE	
Amino acids	B05BA01	0	• No special advice
Aminoacridine	D08AA02	0	• No special advice
Aminobenzoic acid	D02BA01	0	• No special advice
Aminobutyric acid (GABA)	N03AG03	NE	
Aminomethylbenzoic Acid	B02AA03	NE	
Aminophenazone	N02BB03	NE	
Aminophenazone, combinations excl. Psycholeptics	N02BB53	NE	
Aminophenazone, combinations with. Psycholeptics	N02BB73	NE	
Aminophylline	R03DA05	0 I	Oral: • No special advice Parenteral: • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (insomnia, confusion, anxiety, vertigo, dizziness, tremor, visual disturbances) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Aminophylline and adrenergics	R03DB05	NE	
Aminophylline, combinations	R03DA55	NE	
Amiocaproic acid	B02AA01	0	• No special advice
Amiodarone	C01BD01	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Amisulpride	N05AL05	II	• Inform the patient about the effects of the medicine on reaction time and that the

			<p>medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Amitriptyline	N06AA09	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Amitriptyline and psycholeptics	N06CA01	NE	
Amitriptyline and psycholeptics	N06CA01	NE	
Amlexanox	A01AD07 R03DX01	NE	
Amlodipine	C08CA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ammonium chloride	B05XA04	0	<ul style="list-style-type: none"> • No special advice
Amobarbital	N05CA02	NE	
Amorolfine	D01AE16	0	<ul style="list-style-type: none"> • No special advice
Amoxapine	N06AA17	NE	
Amphotericin B	A01AB04 A07AA07	0	<ul style="list-style-type: none"> • No special advice
Ampicilin	S01AA19	NE	
Amrinone	C01CE01	NE	
Ancrod	B01AD09	NE	

Androstanolone	A14AA01	NE	
Anecortave	S01LA02	NE	
Anethole trithione	A16AX02	NE	
Angiotensinamide	C01CX06	NE	
Anileridine	N01AH05	NE	
Aniracetam	N06BX11	NE	
Anistreplase	B01AD03	NE	
Antazoline	R01AC04 R06AX05	NE	
Antibiotics in combination with other drugs	S01AA20	Depending on the medicine in combination	Depending on the medicine in combination
Antiinfectives, combinations	S02AA30	0	• No special advice
Antiinfectives, combinations	S03AA30	0	• No special advice
Antimony pentasulfide	R05CA07	NE	
Antithrombin III	B01AB02	0	• No special advice
Apomorphine	N04BC07	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient not to drive if the medication makes you sleepy. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Apraclonidine	S01EA03	II	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause fatigue and/or drowsiness, blurred and/or abnormal vision which may impair the ability to drive or operate machinery, especially at night or in reduced lighting. • Advise the patient that he/she should wait until these symptoms have cleared before driving or using machinery.
Aprepitant	A04AD12	0	• No special advice
Aprindine	C01BB04	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

		II	<ul style="list-style-type: none"> - Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> - Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia).</p> <p><u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> - Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. - Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
		III	<ul style="list-style-type: none"> - Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Artificial tears and other indifferent preparations	S01XA20	0	<ul style="list-style-type: none"> • No special advice
Ascorbic acid	S01XA15	NE	
Astemizole	R06AX11	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (somnolence, insomnia, drowsiness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Atenolol	C07AB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Atenolol - chlortalidone	C07FB03	NE	
Atenolol - nifedipine	C07FB03	NE	
Atenolol and other antihypertensives	C07FB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Atenolol and other diuretics	C07CB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Atenolol and other diuretics, combinations	C07CB53	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Atenolol and thiazide	C07BB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Atenolol, thiazides and other diuretics	C07DB01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Atomoxetine	N06BA09	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Atorvastatin	C10AA05	0	<ul style="list-style-type: none"> • No special advice
Atorvastatin and amlodipine	C10BX03	NE	
Atracurium	M03AC04	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the

			anaesthetic, and the immediate effects of surgery have passed. <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Atropine	A03BA01	III	<ul style="list-style-type: none"> • Inform the patient that this medication may cause dilated pupils with loss of accommodation and photophobia and increased intraocular pressure and headache, mental confusion or excitement (especially in the elderly), drowsiness, which may impair their ability to drive. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Atropine	S01FA01	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient blurring of vision or that he/she may suffer from photophobia and that this may impair their ability to drive under certain circumstances. Complete recovery from the effects of mydriatic anticholinergics may take up to 24 hours. • Advise the patients not to drive or operate hazardous machinery until 24 hours after receiving ocular medication (recovery occurs within 24 hours) or until vision is clear.
Atropine and psycholeptics	A03CB03	NE	
Atropine+escopolamine+phenylephrine	S01FAP1	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient blurring of vision or that he/she may suffer from photophobia and that this may impair their ability to drive under certain circumstances. Complete recovery from the effects of mydriatic anticholinergics may take up to 24 hours. • Advise the patients not to drive or operate hazardous machinery until 24 hours after receiving ocular medication (recovery occurs within 24 hours) or until vision is clear.
Attapulgit	A07BC04	NE	
Attapulgit, combinations (combination with morphine)	A07BC54	II	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects (dizziness, drowsiness and somnolence) Patients receiving it should not drive or operate machinery unless it has been shown that their physical and mental capacity remains unaffected. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights). • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Auranofin	M01CB03	NE	
Aurothioglucose	M01CB04	NE	

Aurotioprol	M01CB05	NE	
Azapetine	C04AX30	NE	
Azapropazone	M01AX04	NE	
Azatadine	R06AX09	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Azelaic acid	D10AX03	0	<ul style="list-style-type: none"> • No special advice
	R06AX19	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (drowsiness, somnolence) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Azelastine	S01GX07	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Azelastine antazoline	R01AC03	0	<ul style="list-style-type: none"> • No special advice
Azidamfenicol	S01AA25	NE	
Azithromycin	S01AA26	0	<ul style="list-style-type: none"> • No special advice
B	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Bacitracin	D06AX05	0	<ul style="list-style-type: none"> • No special advice
Bacitracin	R02AB04	NE	
Baclofen	M03BX01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness,

			<p>sleepiness, blurred/double vision and reduced alertness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Balsalazide	A07EC04	0	• No special advice
Bambuterol	R03CC12	NE	
Bamethan	C04AA31	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Bamifylline	R03DA08	NE	
Bamipine	D04AA15 R06AX01	NE	
Barbexaclone	N03AA04	NE	
Barbital	N05CA04	NE	
Barbiturates in combinations with other drugs	N05CB02	NE	
Barnidipine	C08CA12	NE	
Batroxobin	B02BX03	NE	
Becaplermin	A01AD08 D03AX06	0	• No special advice
Beclamide	N03AX30	NE	
Beclometasone	A07EA07 D07AC15 R01AD01 R03BA01	0	• No special advice
Beclometasone and antibiotics	D07CC04	0	• No special advice
Befunolol	S01ED06	I	• Inform the patient that as with any ocular medication, if transient, blurred vision

			occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Belladonna total alkaloids	A03BA04	NE	
Belladonna total alkaloids and psycholeptics	A03CB02	NE	
Bemegrade	R07AB05	NE	
Bemiparin	B01AB12	0	• No special advice
Benazepril	C09AA07	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Benazepril and diuretics	C09BA07	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Bencyclane	C04AX11	NE	
Bendazac	M02AA11 S01BC07	NE	
Bendroflumethiazide	C03AA01	0	• No special advice
Bendroflumethiazide and potassium	C03AB01	0	• No special advice
Bendroflumethiazide and potassium-sparing agents (spiro lactone)	C03EA13	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Benflumethiazide - reserpine	C02LA01	NE	
Benfluorex	A10BX06 C10AX04	NE	
Benfotiamine	A11DA03	0	• No special advice

	R02AD01	II III	<p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> - Advise the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia).</p> <p><u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> - Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. - Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Benzocaine	R02AD01	0	• No special advice
Benzocetamide	N05BD01	NE	
Benzododecinium	D09AA05	NE	
Benzonatate	R05DB01	NE	
Benzoxonium chloride	A01AB14 D08AJ05	NE	
Benzoyl peroxide	D10AE01	0	• No special advice
Benzoyl peroxide, combinations	D10AE51	0	• No special advice
Benzydamine	A01AD02 M02AA05	0	• No special advice
Benzydamine	M01AX07	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Benzylpenicilin	S01AA14	NE	
Bepidil	C08EA02	NE	
Beraprost	B01AC19	NE	
Bergapten	D05BA03	NE	
Betacarotene	A11CA02	0	• No special advice

	D02BB01		
Betahistine	N07CA01	I	<ul style="list-style-type: none"> • The treatment has to be used according to the recommended dose to avoid side effect on driving. • Vertigo and hearing loss requiring this treatment can also impair ability to drive.
Betaine	A16AA06	0	<ul style="list-style-type: none"> • No special advice
Betaine hydrochloride	A09AB02	NE	
Betamethasone	A07EA04 C05AA05 D07AC01 D07XC01 R01AD06	0	<ul style="list-style-type: none"> • No special advice
Betamethasone	R03BA04 S01BA06 S02BA07 S03BA03	NE	
Betamethasone (Corticosteroids/antiinfectives/ mydriatics in combination)	S01CB04	Depending on the mydriatic in combination	<ul style="list-style-type: none"> • Depending on the mydriatic in combination
Betamethasone and antibiotics	D07CC01	0	<ul style="list-style-type: none"> • No special advice
Betamethasone and antiinfectives - Drops - Ointment	S01CA05	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Betamethasone and antiinfectives	S03CA06	0	<ul style="list-style-type: none"> • No special advice
Betamethasone and antiseptics	D07BC01	0	<ul style="list-style-type: none"> • No special advice
Betamethasone and mydriatics	S01BB04	Depending on the mydriatic in combination	<ul style="list-style-type: none"> • Depending on the mydriatic in combination
Betanidine	C02CC01	NE	
Betaxolol	C07AB05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Betaxolol	S01ED02	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Betaxolol, combinations	S01ED52	NE	
Bethanechol	N07AB02	NE	
Bevantolol	C07AB06	NE	
Bevantolol and thiazides	C07BB06	NE	
Bevonium	A03AB13	NE	
Bevonium and Analgesics	A03DA03	NE	
Bevonium and psycholeptics	A03CA06	NE	
Bezafibrate	C10AB02	0	<ul style="list-style-type: none"> • No special advice
Bezitramide	N02AC05	NE	
Bibenzonium bromide	R05DB12	NE	
Bibrocathol	S01AX05	NE	
Bietaserpine	C02AA07	NE	
Bietaserpine and diuretics	C02LA07	NE	
Bietaserpine, combinations	C02AA57	NE	
Bifemelane	N06AX08	NE	
Bifonazole	D01AC10	NE	
Bifonazole, combinations	D01AC60	NE	
Bimatoprost	S01EE03	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Biotin	A11HA05	0	<ul style="list-style-type: none"> • No special advice
Biperiden - Oral administration - Parenteral administration	N04AA02	II III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period.

			<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Biphenylol	D08AE06	NE	
Bisacodyl	A06AB02 A06AG02	0	<ul style="list-style-type: none"> • No special advice
Bisacodyl, combinations	A06AB52	0	<ul style="list-style-type: none"> • No special advice
Bismuth preparations, combinations	C05AX02	0	<ul style="list-style-type: none"> • No special advice
Bismuth subcitrate	A02BX05	0	<ul style="list-style-type: none"> • No special advice
Bismuth subnitrate	A02BX12	NE	
Bisoprolol	C07AB07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Bisoprolol - hydrochlorothiazide	C07BB Not yet determined	NE	
Bisoprolol and thiazide	C07BB07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Bisoprolol, combinations	C07AB57	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Bisoxatin	A06AB09	NE	
Bithionol	D10AB01	NE	
Bitolterol	R03AC17	NE	

Bivalirudin	B01AE06	0	• No special advice
Blood plasma	B05AX03	NE	
Bopindolol	C07AA17	NE	
Bopindolol and other diuretics	C07CA17	NE	
Boric acid	S02AA03	NE	
Bornaprine	N04AA11	NE	
Bosentan	C02KX01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Botulinum toxin A Botulinum toxin B	M03AX01	II II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (muscle weakness, somnolence, dizziness and visual disturbance) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Bretylium tosilate	C01BD02	NE	
Brimonidine	S01EA05	II	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause fatigue and/or drowsiness, blurred and/or abnormal vision which may impair the ability to drive or operate machinery, especially at night or in reduced lighting. • Advise the patient that he/she should wait until these symptoms have cleared before driving or using machinery.
Brinase	B01AD06	NE	
Brinzolamide	S01EC04	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Bromazepam	N05BA08	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can

			<p>also be reduced without experiencing side effects.</p> <ul style="list-style-type: none"> • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days. Advise your patient not to drive then.
Bromazine	R06AA01	NE	
Bromelains	B06AA11	NE	
Bromhexine	R05CB02	0	<ul style="list-style-type: none"> • No special advice
Bromides	N05CM11	NE	
Bromisoval	N05CM03	NE	
Bromochlorosalicylanilide	D01AE01	NE	
Bromocriptine	N04BC01	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen during the dosage adjustment period. • Advise the patient (and explain to caregivers) to avoid drinking alcohol whilst taking the medicine • Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks". • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).
Bromopride	A03FA04	NE	
Bromperidol - Oral administration - Parenteral administration: depot i.m.	N05AD06	II	<p>Oral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
		III	Parenteral administration

			<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Brompheniramine	R06AB01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Brompheniramine, combinations	R06AB51	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Brotizolam	N05CD09	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 24 hours. Advise your patient not to drive then.
Broxyquinoline	A07AX01	NE	
Bucetin	N02BE04	NE	

Bucetin, combinations excl. Psycholeptics	N02BE54	NE	
Bucetin, combinations with Psycholeptics	N02BE74	NE	
Bucillamine	M01CC02	NE	
Bucladesine	C01CE04	NE	
Buclizine	R06AE01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Buclizine, combinations	R06AE51	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Budesonide	A07EA06 D07AC09 R01AD05 R03BA02	0	<ul style="list-style-type: none"> • No special advice
Budipine	N04BX03	NE	
Bufexamac	M01AB17 M02AA09	NE	
Buflomedil	C04AX20	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.

Buformin	A10BA03	NE	
Buflin	R03DA10	NE	
Bumadizone	M01AB07	NE	
Bumetanide	C03CA02	0	• No special advice
Bumetanide and potassium	C03CB02	0	• No special advice
Bumetanide and potassium-sparing agents	C03EB02	0	• No special advice
Bunaftine	C01BD03	NE	
Buphenine	C04AA02	I	Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Bupivacaine	N01BB01	0 I II III	Categorization, labelling and information to the patient depending of the route of administration <u>Topic administration</u> (skin, mucous) <u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <u>Ocular administration:</u> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after

			anaesthesia
Bupivacaine combinations	N01BB51	0 I II III	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Bupranolol	C07AA19	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Buprenorphine - Oral administration - Parenteral admin. - Transdermal admin	N02AE01	III III III/II* *) prolonged release formulation; when a steady state of	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme.

		dosage has been reached	<ul style="list-style-type: none"> • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Buprenorphine - Oral administration: - Transdermal patch: - Parenteral administration:	N07BC01	II II III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • Advise the patient to strictly follow the prescribed doses, the treatment and delivery procedures and to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioural changes and requires follow-up and counselling. • Driving with this treatment should require an approval by driving licence administration.
Buprenorphine, combinations (buprenorphine+naloxone)	N07BC51	III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • Advise the patient to strictly follow the prescribed doses, the treatment and delivery procedures and to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioural changes and requires follow-up and counselling. • Driving with this treatment should require an approval by driving licence administration.
Bupropion (amfebutamone)	N07BA02	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • The treatment has to be used according to the recommended dose. • Advise the patient about possible effects on behavior. • Smoking cessation can also cause behavioural changes.
Buspirone	N05BE01	I	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few hours after taking the medicine and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when

			taking this medicine.
Butalamine	C04AX23	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Butamirate	R05DB13	NE	
Butanilicaine	N01BB05	NE	
Butaperazine	N05AB09	NE	
Butenafine	D01AE23	NE	
Butizide and potassium-sparing agents(spironolactone)	C03EA14	NE	
Butobarbital	N05CA03	NE	
Butorphanol	N02AF01	NE	
Butriptyline	N06AA15	NE	
Butylscopolamine - Oral administration	A03BB01	I	<p>Oral administration</p> <ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. possible visual accommodation disturbances), and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
- Parenteral administration (i.v)		II	<p>Parenteral administration</p> <ul style="list-style-type: none"> Inform the patient that this medication causes visual accommodation disturbances so you should not drive or operate machinery after parenteral administration until vision has normalised. Advise the patient that he should wait until his sight returns to normal before driving or using any tools or machines.
Butylscopolamine and analgesics. - Oral administration	A03DB04	I	<p>Oral administration</p> <ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. possible visual accommodation disturbances), and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.

- Parenteral administration		II	Parenteral administration <ul style="list-style-type: none"> • Inform the patient that this medication causes visual accommodation disturbances so you should not drive or operate machinery after parenteral administration until vision has normalised. • Advise the patient that he should wait until his sight returns to normal before driving or using any tools or machines.
C	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
C1-inhibitor	B02AB03	0	<ul style="list-style-type: none"> • No special advice
Cabergoline	N04BC06	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks” • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Cadexomer iodine	D03AX01	NE	
Cadmium compounds	D11AC02	0	<ul style="list-style-type: none"> • No special advice
Cadralazine	C02DB04	NE	
Cafedrine	C01CA21	NE	
Caffeine	N06BC01	NE	
Calcifediol	A11CC06	0	<ul style="list-style-type: none"> • No special advice
Calcipotriol	D05AX02	0	<ul style="list-style-type: none"> • No special advice
Calcipotriol, combinations	D05AX52	0	<ul style="list-style-type: none"> • No special advice
Calcitriol	A11CC04 D05AX03	0	<ul style="list-style-type: none"> • No special advice
Calcium (different salts in combination)	A12AA20	0	<ul style="list-style-type: none"> • No special advice
Calcium acetate anhydrous	A12AA12	0	<ul style="list-style-type: none"> • No special advice
Calcium alginate	B02BC08	NE	

Calcium carbasalate - metoclopramide	N02BA15	NE	
Calcium carbimide	N07BB02	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • Advise the patient to strictly follow the prescribed doses and to avoid any alcohol or other psychoactive substances during the treatment. • Alcohol cessation can also cause behavioural changes and requires follow-up and counselling. • Driving with this treatment should require an approval by driving licence administration.
Calcium carbonate	A02AC01 A12AA04	0	<ul style="list-style-type: none"> • No special advice
Calcium chloride	A12AA07 B05XA07	0	<ul style="list-style-type: none"> • No special advice
Calcium citrate lysine complex	A12AA09	0	<ul style="list-style-type: none"> • No special advice
Calcium compounds	A07XA03	NE	
Calcium dobesilate	C05BX01	0	<ul style="list-style-type: none"> • No special advice
Calcium dobesilate, combinations	C05BX51	0	<ul style="list-style-type: none"> • No special advice
Calcium glubionate	A12AA02	0	<ul style="list-style-type: none"> • No special advice
Calcium glucoheptonate	A12AA10	0	<ul style="list-style-type: none"> • No special advice
Calcium gluconate	A12AA03	0	<ul style="list-style-type: none"> • No special advice
Calcium gluconate	D11AX03	NE	
Calcium glycerylphosphate	A12AA08	0	<ul style="list-style-type: none"> • No special advice
Calcium hexamine thiocyanate	R01AX01	NE	
Calcium lactate	A12AA05	0	<ul style="list-style-type: none"> • No special advice
Calcium lactate gluconate	A12AA06	0	<ul style="list-style-type: none"> • No special advice
Calcium laevulate	A12AA30	0	<ul style="list-style-type: none"> • No special advice
Calcium pangamate	A12AA11	0	<ul style="list-style-type: none"> • No special advice
Calcium pantothenate	A11HA31 D03AX04	NE	
Calcium phosphate	A12AA01	0	<ul style="list-style-type: none"> • No special advice
Calcium silicate	A02AC02	0	<ul style="list-style-type: none"> • No special advice

Camazepam	N05BA15	NE	
Camolenic acid	D11AX02	NE	
Camostat	B02AB04	NE	
Camphora	C01EB02	NE	
Camylofin	A03AA03	NE	
Camylofin and analgesics	A03DA05	NE	
Candesartan	C09CA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Candesartan and diuretics	C09DA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Canrenone	C03DA03	NE	
Capsaicin	M02AB01 N01BX04	0	<ul style="list-style-type: none"> • No special advice
Captodiame	N05BB02	NE	
Captopril	C09AA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Captopril and diuretics	C09BA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Carbachol	N07AB01 S01EB02	NE	
Carbamazepine	N03AF01	II	Advise the patient not to drive during the first days of treatment as well as after dose increases.

			<p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication. <p>Trigeminal neuralgia and prophylaxis of manic-depressive psychosis;</p> <ul style="list-style-type: none"> • Advise the patient not to drive during the first days of treatment as well as after dose increases.
Carbamide	B05BC02	NE	
Carbamide	D02AE01	0	• No special advice
Carbamide, combinations	D02AE51	0	• No special advice
Carbamide products	D02AE	0	• No special advice
Carbasalate calcium	B01AC08	0	• No special advice
Carbasalate calcium combinations excl. Psycholeptics	N02BA65	NE	
Carbazochrome	B02BX02	NE	
Carbenoxolone	A02BX01	0	• No special advice
Carbenoxolone, combinations excl. psycholeptics	A02BX51	NE	
Carbenoxolone, combinations with psycholeptics	A02BX77	NE	
Carbinoxamine	R06AA08	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Carbocisteine	R05CB03	0	• No special advice

Carbocromen	C01DX05	NE	
Carbohydrates	B05BA03	0	• No special advice
Carbon dioxide producing drugs	A06AX02	NE	
Carbromal	N05CM04	NE	
Carbutamide	A10BB06	NE	
Carbuterol	R03AC10 R03CC10	NE	
Cardioplegia solutions	B05XA16	0	• No special advice
Carglumic acid	A16AA05	0	• No special advice
Carisoprodol	M03BA02	II	• Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness)
Carisoprodol, combinations excl. psycholeptics	M03BA52	II	• Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights)
Carisoprodol, combinations with psycholeptics	M03BA72	II	• Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then
Caroverine	A03AX11	NE	
Carteolol	C07AA15	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
	S01ED05	I	• Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Carteolol, combinations	S01ED55	NE	
Carvedilol	C07AG02	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Cascara	A06AB07	0	<ul style="list-style-type: none"> • No special advice
Cascara, combinations	A06AB57	0	<ul style="list-style-type: none"> • No special advice
Casopitant	A04AD13	NE	
Castor oil	A06AB05	0	<ul style="list-style-type: none"> • No special advice
Cathine	A08AA07	NE	
Celecoxib	M01AH01	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Celiprolol	C07AB08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ceratonia	A07XA02	NE	
Cerium oxalate	A04AD02	NE	
Cerivastatin	C10AA06	NE	
Cetiedil	C04AX26	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Cetirizine	R06AE07	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights)

			<ul style="list-style-type: none"> • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Cetrimide	D08AJ04 D11AC01	0	<ul style="list-style-type: none"> • No special advice
Cetrimonium	D08AJ02	0	<ul style="list-style-type: none"> • No special advice
Cetrimonium	R02AA17	NE	
Cetylpyridinium	B05CA01	NE	
Cetylpyridinium	D08AJ03 D09AA07 R02AA06	0	<ul style="list-style-type: none"> • No special advice
Chenodeoxycholic acid	A05AA01	NE	
Chloral hydrate	N05CC01	NE	
Chloralodol	N05CC02	NE	
Chloramphenicol	D06AX02 D10AF03	0	<ul style="list-style-type: none"> • No special advice
Chloramphenicol - Drops - Ointment	S01AA01	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Chloramphenicol	S02AA01 S03AA08	NE	
Chlorbenzoxamine	A03AX03	NE	
Chlorcyclizine	R06AE04	NE	
Chlordiazepoxide	N05BA02	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for 3 days. Advise your patient not to drive then.

Chlorhexidine	A01AB03 D08AC02 D09AA12 R02AA05	0	• No special advice
Chlorhexidine	B05CA02 S02AA09 S03AA04	NE	NE
Chlorhexidine, combinations	D08AC52	0	• No special advice
Chlormezanone	M03BB02	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Chlormezanone, combinations excl. psycholeptics	M03BB52	II	
Chlormezanone, combinations with psycholeptics	M03BB72	II	
Chlormidazole	D01AC04	NE	
Chlorobutanol	A04AD04	NE	
Chlorobutanol, combinations	A04AD54	0	• No special advice
Chloroform	N01AB02	NE	
Chloroprednisolone and antiinfectives	S01CA09	NE	
Chloroprocaine	N01BA04	NE	
Chloropyramine	D04AA09 R06AC03	NE	
Chloropyramine, combinations	R06AC53	NE	
Chlorothiazide	C03AA04	NE	
Chlorothiazide and potassium	C03AB04	NE	
Chlorothiazide, combinations	C03AH01	NE	
Chloroxylenol	D08AE05	0	• No special advice
Chlorphenamine	R06AB04	II	• Inform the patient about the effects of the medicine on reaction time and that the

			<p>medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Chlorphenamine, combinations	R06AB54	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Chlorphenesin	D01AE07	NE	
Chlorphenoxamine	D04AA34	NE	
Chlorphenoxamine	R06AA06	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Chlorphenoxamine, Combinations	R06AA56	NE	
Chlorproethazine	N05AA07	NE	
Chlorpromazine *Oral administration *Parenteral administration	N05AA01	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.

			<ul style="list-style-type: none"> • In short-term use (eg intractable hiccup, nausea and vomiting) inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Chlorpropamide	A10BB02	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Chlorprothixene	N05AF03	NE	
Chlorquinaldol	D08AH02	0	<ul style="list-style-type: none"> • No special advice
Chlorquinaldol	R02AA11	NE	
Chlortalidone	C03BA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Chlortalidone and potassium	C03BB04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Chlortalidone and potassium-sparing agents (spiro lactone)	C03EA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Chlortetracycline	A01AB21 D06AA02	0	<ul style="list-style-type: none"> • No special advice
Chlortetracycline - Drops	S01AA02	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application.

- Ointment			<ul style="list-style-type: none"> • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Chlorzoxazone	M03BB03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness)
Chlorzoxazone, combinations excl. psycholeptics	M03BB53	II	<ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Chlorzoxazone, combinations with psycholeptics	M03BB73	II	
Cholic acid	A05AA03	NE	
Choline alfoscerate	N07AX02	NE	
Choline salicylate	N02BA03	NE	
Choline theophyllinate	R03DA02	NE	
Choline theophyllinate and adrenergics	R03DB02	NE	
Chondroitin sulfate	M01AX25	NE	
Chondroitin sulfate-iron complex	B03AB07	NE	
Chymopapain	M09AB01	NE	
Chymotrypsin	B06AA04 S01KX01	NE	
Cibenzoline	C01BG07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ciclesonide	R03BA08	0	<ul style="list-style-type: none"> • No special advice
Cicletanine	C03BX03	0	<ul style="list-style-type: none"> • No special advice
Ciclonicate	C04AC07	NE	
Ciclonium and analgesics	A03DA04	NE	

Ciclopirox	D01AE14	0	• No special advice
Ciclosporin	S01XA18	NE	
Cilansetron	A03AE03	NE	
Cilazapril	C09AA08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Cilazapril and diuretics	C09BA08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Cilnidipine	C08CA14	NE	
Cilostazol	B01AC	0	• No special advice
Cimetidine	A02BA01	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Cimetidine, combinations	A02BA51	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Cimetropium bromide	A03BB05	NE	
Cinchocaine	C05AD04 D04AB02	0	• No special advice
Cinchocaine	N01BB06 S01HA06	NE	
Cinchophen	M04AC02	NE	
Cinepazet	C01DX14	NE	
Cinepazide	C04AX27	NE	
Cinitapride	A03FA (not ATC code)	0	• No special advice
Cinnarizine	N07CA02	II	• Advise the patient (and explain to caregivers) not to drive during the first days of

			<p>treatment.</p> <ul style="list-style-type: none"> • The treatment has to be used according to the recommended dose. • Vertigo and hearing loss requiring this treatment can also impair ability to drive.
Cinnarizine, combinations	N07CA52	NE	
Cinolazepam	N05CD13	NE	
Ciprofibrate	C10AB08	0	<ul style="list-style-type: none"> • No special advice
Ciprofloxacin - Drops - Ointment	S01AX13	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Ciprofloxacin	S02AA15	0	<ul style="list-style-type: none"> • No special advice
Ciprofloxacin	S03AA07	NE	
Cisapride	A03FA02	0	<ul style="list-style-type: none"> • No special advice
Cisatracurium	M03AC11	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Citalopram	N06AB04	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Citicoline	N06BX06	NE	
Citicolone	A05BA04	NE	
Citric acid	A09AB04	0	<ul style="list-style-type: none"> • No special advice
Clebopride	A03FA06	0	<ul style="list-style-type: none"> • No special advice
Clemastine	D04AA14	NE	
Clemastine	R06AA04	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (fatigue, drowsiness) • Advise the patient not to drive until the next visit after start of treatment and also to

			<ul style="list-style-type: none"> be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine
Clemastine, combinations	R06AA54	III	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness and reduced alertness) Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Clenbuterol	R03AC14 R03CC13	NE	
Clidinium and psycholeptics	A03CA02	NE	
Clindamycin	D10AF01	0	<ul style="list-style-type: none"> No special advice
Clindamycin, combinations	D10AF51	0	<ul style="list-style-type: none"> No special advice
Clioquinol	D08AH30	0	<ul style="list-style-type: none"> No special advice
Clioquinol	D09AA10 S02AA05	0	<ul style="list-style-type: none"> No special advice
Clobazam	N05BA09	II	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Clobenzorex	A08AA08	NE	
Clobetasol	D07AD01	0	<ul style="list-style-type: none"> No special advice
Clobetasol and antibiotics	D07CD01	NE	
Clobetasone	D07AB01	0	<ul style="list-style-type: none"> No special advice

Clobetasone	S01BA09	NE	
Clobetasone and antiinfectives	S01CA11	NE	
Clobutinol	R05DB03	NE	
Clocortolone	D07AB21	NE	
Clodronic acid	M05BA02	0	• No special advice
Clofedanol	R05DB10	NE	
Clofenamide	C03BA07	NE	
Clofenamide and potassium	C03BB07	NE	
Clofezone	M01AA05 M02AA03	NE	
Clofibrate	C10AB01	NE	
Clofibride	C10AB10	NE	
Clomethiazol	N05CM02	I	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first 8 hours after taking the medicine and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Clomipramine	N06AA04	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Clonazepam - Oral administration	N03AE01	II III	Advise the patient not to drive during the first days of treatment as well as after dose increases.

- Parenteral administration			<p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Clonidine	C02AC01	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). <p>Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.</p>
	N02CX02	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
	S01EA04		<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause fatigue and/or drowsiness, blurred and/or abnormal vision which may impair the ability to drive or operate machinery, especially at night or in reduced lighting. • Advise the patient that he/she should wait until these symptoms have cleared before driving or using machinery.
Clonidine and diuretics	C02LC01	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.

Clonidine and diuretics, combinations with other drugs	C02LC51	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Clonixin	N02BG Not yet determined	NE	
Clopamide	C03BA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Clopamide and potassium	C03BB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Clopendithiol	N05AF02	NE	
Cloperastine	R05DB21	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (drowsiness, sedation, accommodation disorder) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Clopidogrel	B01AC04	0	<ul style="list-style-type: none"> • No special advice
Clopidogrel + Acetilsalicylic acid	B01AC30	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Cloranolol	C07AA27	NE	
Clorazepate combinations	N05CX04	NE	
Clorexolone	C03BA12	NE	

Clorexolone, comb. with psycholeptics	C03BA82	NE	
Clorhexidine	S01AX09	NE	
Cloricromen	B01AC02	NE	
Cloridarol	C01DX15	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Clorindione	B01AA09	NE	
Clotiapine - Oral administration - Parenteral administration: i.m./i.v.	N05AX09	II III	<p>Oral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then. <p>Parenteral administration</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Clotiazepam	N05BA21	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects.

			<ul style="list-style-type: none"> • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days. Advise your patient not to drive then.
Clotrimazole	A01AB18	NE	
Clotrimazole	D01AC01	0	<ul style="list-style-type: none"> • No special advice
Clovoxamine	N06AA Not yet determined	NE	
Cloxacolam	N05BA22	NE	
Clozapine	N05AH02	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Coagulation factor IX	B02BD04	0	<ul style="list-style-type: none"> • No special advice
Coagulation factor IX, II, VII and X in combination	B02BD01	0	<ul style="list-style-type: none"> • No special advice
Coagulation factor VII (in combination with other factors)	B02BD05	0	<ul style="list-style-type: none"> • No special advice
Coagulation factor VIII	B02BD02	0	<ul style="list-style-type: none"> • No special advice
Coagulation factor XIII	B02BD07	NE	
Cobamamide	B03BA04	0	<ul style="list-style-type: none"> • No special advice
Cocaine	N01BC01 R02AD03 S01HA01 S02DA02	NE	
Cod-liver oil ointments	D03AA	0	<ul style="list-style-type: none"> • No special advice
Codeine	R05DA04		> 20 mg:

> 20 mg		II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, confusion, tiredness, vertigo, blurred vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
≤ 20 mg		I	<p>≤ 20 mg:</p> <ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, confusion, tiredness, vertigo, blurred vision and reduced alertness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Codeine, combinations excl .psycholeptics	N02AA59		
> 20 mg		II	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights)
≤ 20 mg		I	<ul style="list-style-type: none"> • When using more than 20mg: Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Codeine, combinations with psycholeptics	N02AA79	NE	
Colchicine	M04AC01	0	• No special advice
Colecalciferol	A11CC05	0	• No special advice
Colesevelam	C10AC04	0	• No special advice
Colestipol	C10AC02	0	• No special advice
Colestyramine	C10AC01	0	• No special advice
Colextran	C10AC03	0	• No special advice

Colfosceril palmitate	R07AA01	NE	
Colistin	A07AA10	0	• No special advice
Collagen	B02BC07	NE	
Collagen, combinations	D11AX57	NE	
Collagenase	D03BA02	NE	
Collagenase, combinations	D03BA05	NE	
Comb. of rauwolfia alkaloids and diuretics incl. other combinations	C02LA50	NE	
Combinations (Adrenergic and dopaminergic agents)	C01CA30	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Combinations (Aluminium compounds)	A02AB10	0	• No special advice
Combinations (Analgesics and anesthetics)	S02DA30	Depending on the medicine in combination	• Depending on the medicine in combination
Combinations (Anesthetics, local, amides)	N01BB20	NE	
Combinations (Antifungals for topical use, Antibiotics)	D01AA20	NE	
Combinations (Butylpyrazolidine)	M01AA99	NE	
Combinations (Calcium compounds)	A02AC10	0	• No special advice
Combinations (Caries prophylactic agents)	A01AA30	NE	
Combinations (Enemas)	A06AG20	0	• No special advice
Combinations (Expectorants)	R05CA10	NE	
Combinations (Imidazole and triazole derivatives)	D01AC20	NE	
Combinations (Insulins and	A10AB30	I	• Advise your patient to take precautions to avoid hypoglycaemia, this may constitute

analogues for injection, fast-acting)			a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist.
Combinations (Insulins and analogues for injection, intermediate-acting)	A10AC30	I	<ul style="list-style-type: none"> • If your patient have frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances.
Combinations (Insulins and analogues for injection, intermediate-acting combined with fast-acting)	A10AD30	I	<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Combinations (Insulins and analogues for injection, long-acting)	A10AE30	I	
Combinations (Irrigating solutions, Antiinfectives)	B05CA10	NE	
Combinations (Irrigating solutions, Salt solutions)	B05CB10	0	<ul style="list-style-type: none"> • No special advice
Combinations (Local anesthetics)	S01HA30	I	<ul style="list-style-type: none"> • Inform the patient that his/her eyesight may become blurred. • Advise him/her not to drive or operate machinery during the first 24 hours following the use of a local anaesthetic.
Combinations (Local hemostatics)	B02BC30	0	<ul style="list-style-type: none"> • No special advice
Combinations (Lung surfactants)	R07AA30	NE	
Combinations (Magnesium compounds)	A02AA10	0	<ul style="list-style-type: none"> • No special advice
Combinations (Mucolytics)	R05CB10	NE	
Combinations (Opium alkaloids and derivatives)	R05DA20	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Combinations (Other cough suppressants)	R05DB20	NE	
Combinations (Other intestinal adsorbents)	A07BC30	NE	
Combinations (Other irrigating)	B05CX10	0	<ul style="list-style-type: none"> • No special advice

solutions)			
Combinations (Other nasal preparations)	R01AX30	NE	
Combinations (Platelet aggregation inhibitors excl. heparin)	B01AC30	Depending on the medicine in combination	• Depending on the medicine in combination
Combinations (Solutions for parenteral nutrition)	B05BA10	0	• No special advice
Combinations (Vitamin A and D, incl. combinations of the two)	A11CC20	Depending on the medicine in combination	• Depending on the medicine in combination
Combinations of barbiturates	N05CB01	NE	
Combinations of corticosteroids	D07AB30 D07XB30	0	• No special advice
Combinations of different antibiotics	S01AA30	Depending on the medicine in combination	• Depending on the medicine in combination
Combinations of electrolytes	B05XA30	0	
Combinations of rauwolfia alkaloids	C02AA03	NE	
Combinations of rauwolfia alkaloids, combinations	C02AA53	NE	
Combinations of xanthines	R03DA20	NE	
Combinations (Other antifungals for topical use)	D01AE20	NE	
Combinations, (potassium)	A12BA30	Depending on the medicine in combination	• Depending on the medicine in combination
Conivaptan	C03XA02	NE	
Contact laxatives in combination	A06AB20	0	• No special advice
Contact laxatives in combination with belladonna alkaloids	A06AB30	NE	

Cortisone	S01BA03	NE	
Cosfocreatine	C01EB06	NE	
Cough suppressants and expectorants	R05FB02	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Cough suppressants and mucolytics	R05FB01	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Crataegus glycosides	C01EB04	NE	
Creatinolfosfate	C01EB05	NE	
Creosote	R05CA08	NE	
Cromoglicic acid	A07EB01 R01AC01 R03BC01	0	<ul style="list-style-type: none"> • No special advice
Cromoglicic acid	D11AH03	NE	
Cromoglicic acid	S01GX01	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Cromoglicic acid, combinations	R01AC51 S01GX51	NE	
Crospovidone	A07BC03	NE	
Curcuma	A05AX Not yet determined	0	<ul style="list-style-type: none"> • No special advice
Cxyphenonium, combinations	A03AB53	NE	
Cyacobalamin	B03BA01	0	<ul style="list-style-type: none"> • No special advice
Cyamemazine	N05AA06	NE	
Cyanocobalamin tannin complex	B03BA02	NE	
Cyanocobalamin, combinations	B03BA51	0	<ul style="list-style-type: none"> • No special advice
Cyclandelate	C04AX01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair

			<p>his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.</p> <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Cyclizine	R06AE03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Cyclizine, combinations	R06AE53	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Cyclobarbital	N05CA10	NE	
Cyclobenzaprine	M03BX08	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Cyclobutylol	A05AX03	0	<ul style="list-style-type: none"> • No special advice
Cyclopentamine	R01AA02	NE	
Cyclopenthiiazide	C03AA07	0	<ul style="list-style-type: none"> • No special advice
Cyclopenthiiazide and potassium.	C03AB07	NE	
Cyclopenthiiazide and potassium-sparing agents (spironolactone)	C03EA07	NE	

Cyclopentolate	S01FA04	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient blurring of vision or that he/she may suffer from photophobia and that this may impair their ability to drive under certain circumstances. Complete recovery from the effects of mydriatic anticholinergics may take up to 24 hours. • Advise the patients not to drive or operate hazardous machinery until 24 hours after receiving ocular medication (recovery occurs within 24 hours) or until vision is clear.
Cyclothiazide	C03AA09	NE	
Cyclothiazide and potassium	C03AB09	NE	
Cymar	C01AC03	NE	
Cyproheptadine	R06AX02	II	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects (dizziness, drowsiness and somnolence) Patients receiving it should not drive or operate machinery unless it has been shown that their physical and mental capacity remains unaffected. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
D	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Dabigatran etexilate	B01AE07	0	<ul style="list-style-type: none"> • No special advice
Dalteparin	B01AB04	0	<ul style="list-style-type: none"> • No special advice
Danaparoid	B01AB09	0	<ul style="list-style-type: none"> • No special advice
Dantrolene	M03CA1	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Dantron	A06AB03	0	<ul style="list-style-type: none"> • No special advice

Dantron, combinations	A06AB53	0	• No special advice
Dantron, incl. Combinations	A06AG03	0	• No special advice
Dapiprazole	S01EX02	NE	
Dapsone	D10AX05	0	• No special advice
Darbepoetin alfa	B03XA02	0	• No special advice
Deanol	N06BX04	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication
Debrisoquine	C02CC04	NE	
Defibrotide	B01AX01	NE	
Delapril	C09AA12	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Delapril and diuretics	C09BA12	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Delapril and manidipine	C09BB12	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Demecarium	S01EB04	NE	
Demeclocycline	D06AA01	NE	

Denosumab	M05BX04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. visual disturbances), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Deptropine	R06AX16	NE	
Dequalinium	D08AH01 R02AA02	0	<ul style="list-style-type: none"> • No special advice
Dermatan sulfate	B01AX04	NE	
Deserpidine	C02AA05	NE	
Deserpidine and diuretics.	C02LA03	NE	
Desflurane	N01AB07	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Desipramine	N06AA01	NE	
Desirudin	B01AE01	0	<ul style="list-style-type: none"> • No special advice
Deslanoside	C01AA07	NE	
Desloratadine	R06AX27	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (drowsiness, fatigue) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Desonide	D07AB08	NE	

	S01BA11		
Desonide and antiseptics	D07BB02	NE	
Desoximetasone	D07AC03	0	• No special advice
Desoximetasone	D07XC02	NE	
Desoxyribonuclease	B06AA10	NE	
Desvenlafaxine	N06AX23	NE	
Dexamafetamine	N06BA02	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Dexamethasone	A01AC02 C05AA09 D07AB19 D07XB05 D10AA03 R01AD03	0	• No special advice
Dexamethasone - Drops - Ointment	S01BA01	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Dexamethasone	S01CB01	Depending on the mydriatic in combination	• Depending on the mydriatic in combination
Dexamethasone	S02BA06 S03BA01	NE	
Dexamethasone and antibiotics	D07CB04	NE	

Dexamethasone and antiinfectives - Drops - Ointment	S01CA01	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Dexamethasone and antiinfectives	S02CA06 S03CA01	0	<ul style="list-style-type: none"> • No special advice
Dexamethasone, combinations	R01AD53	NE	
Dexamfetamine	N06BA02	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Dexbrompheniramine	R06AB06	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Dexbrompheniramine, combinations	R06AB56	NE	
Dexchlorpheniramine	R06AB02	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when

			taking this medicine.
Dexchlorpheniramine Combinations	R06AB52	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Dexetimide	N04AA08	NE	
Dexfenfluramine	A08AA04	NE	
Dexibuprofen	M01AE14	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Dexketoprofen	M01AE17	I	
Dexmedetomidine	N05CM18	NE	
Dexpanthenol	A11HA30	0	<ul style="list-style-type: none"> • No special advice
Dexpanthenol	D03AX03 S01XA12	NE	
Dextran	B05AA05	0	<ul style="list-style-type: none"> • No special advice
Dextranomer	D03AX02	NE	
Dextriferron	B03AB05	NE	
Dextriferron	B03AC01	0	<ul style="list-style-type: none"> • No special advice
Dextriferron (carboximaltosa)	B03AD04	0	<ul style="list-style-type: none"> • No special advice
Dextromethorphan	R05DA09	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, excitation, confusion) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.

Dextromoramide	N02AC01	NE	
Dextropropoxyphene	N02AC04	NE	
Dextropropoxyphene combinations excl. psycholeptics	N02AC54	NE	
Dextropropoxyphene, comb. With psycholeptics	N02AC74	NE	
Dextrothyroxine	C10AX01	NE	
Dezocine	N02AX03	NE	
Diacerein	M01AX21	NE	
Diamorphine	N02AA09	NE	
Diastase	A09AA01	NE	
Diazepam	N05BA01	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Diazoxide	C02DA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Dibenzepin	N06AA08	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.

			<ul style="list-style-type: none"> • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Dibotermin alfa (Kit for implant)	M05BC01	0	<ul style="list-style-type: none"> • No special advice
Dibrompropamidine	D08AC01	0	<ul style="list-style-type: none"> • No special advice
Dibrompropanamidine	S01AX14	NE	
Dibunate	R05DB16	NE	
Dichloralphenazone	N05CC04	NE	
Dichlorobenzyl alcohol	R02AA03	0	<ul style="list-style-type: none"> • No special advice
Diclofenac	M01AB05 N02BG	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Diclofenac (ophtalmologic use)	S01BC03	0	<ul style="list-style-type: none"> • No special advice
Diclofenac (topic use)	M02AA15 D11AX18	0	<ul style="list-style-type: none"> • No special advice
Diclofenac and antiinfectives	S01CC01	0	<ul style="list-style-type: none"> • No special advice
Diclofenac, combinations	M01AB55	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Diclofenamide	S01EC02	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Dicoumarol	B01AA01	NE	
Dicycloverine	A03AA07	0	<ul style="list-style-type: none"> • No special advice
Didecyldimethylammonium chloride	D08AJ06	NE	
Diethyl ether	N01AA01	NE	

Difemerine	A03AA09	NE	
Difenoxin	A07DA04	NE	
Difenpiramide	M01AB12	NE	
Diflorasone	D07AC1 0	0	<ul style="list-style-type: none"> • No special advice
Diflucortolone	D07AC06	0	<ul style="list-style-type: none"> • No special advice
Diflucortolone	D07XC04	NE	
Diflucortolone and antiseptics	D07BC04	0	<ul style="list-style-type: none"> • No special advice
Diflunisal	N02BA11	NE	
Difluprednate	D07AC19	NE	
Digitalis leaves	C01AA03	NE	
Digitoxin	C01AA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Digoxin	C01AA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Dihexyverine	A03AA08	NE	
Dihydralazine	C02DB01	NE	
Dihydralazine and diuretics	C02LG01	NE	
Dihydralazine and diuretics, combinations with other drugs	C02LG51	NE	
Dihydrocodeine	N02AA08	III/II* *)prolonged release formulation; when a steady state of dosage has been reached	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights)

			<ul style="list-style-type: none"> • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Dihydrocodeine combinations	N02AA58	NE	
Dihydroergocristine	C04AE04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Dihydroergocristine, combinations	C04AE54	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Dihydroergocrypti mesylate	N04BC03	NE	
Dihydroergocryptine mesylate	N04BC03	NE	
Dihydroergotamine	N02CA01	NE	
Dihydrostreptomycin	S01AA15	NE	
Dihydrotachysterol	A11CC02	0	<ul style="list-style-type: none"> • No special advice
Dihydroxialumini sodium carbonate	A02AB04	0	<ul style="list-style-type: none"> • No special advice
Diiodohydroxypropane	D08AG04	NE	
Diisopromine	A03AX02	NE	
Dilazep	C01DX10	NE	
Diltiazem	C08DB01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Dimazole	D01AE17	NE	
Dimecrotico acido	It is not in	0	<ul style="list-style-type: none"> • No special advice

	ATC list		
Dimeflin	R07AB08	NE	
Dimemorfan	R05DA11	NE	
Dimetacrine	N06AA18	NE	
Dimethoxanate	R05DB28	NE	
Dimethyl sulfoxide	M02AX03	NE	
Dimethylaminopropionylphenothiazine	A03AC2	NE	
Dimethyltubocurarine	M03AA04	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Dimetindene	D04AA13	0	<ul style="list-style-type: none"> • No special advice
Dimetindene	R06AB03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Dimetofrine	C01CA12	NE	
Dimetotiazine	N02CX05	NE	
Diosmectite	A07BC05	NE	
Diosmin	C05CA03	0	<ul style="list-style-type: none"> • No special advice
Diosmin, combinations	C05CA53	0	<ul style="list-style-type: none"> • No special advice
Diphemanil	A03AB15	NE	
Diphemanil and psycholeptics	A03CA08	NE	
Diphenadione	B01AA10	NE	
Diphenhydramine	D04AA32	0	<ul style="list-style-type: none"> • No special advice
Diphenhydramine	R06AA02	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, blurred vision and reduced alertness)

			<ul style="list-style-type: none"> • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Diphenhydramine methylbromide	D04AA33	0	<ul style="list-style-type: none"> • No special advice
Diphenhydramine, combinations	R06AA52	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Diphenoxylate	A07DA01	NE	
Diphenylpyraline	R06AA07	NE	
Diphenylpyraline, combinations	R06AA57	NE	
Dipiperonylamino-ethanol, combinations	N05CX06	NE	
Dipivefrine	S01EA02	NE	
Diprophylline	R03DA01	NE	
Diprophylline and adrenergics	R03DB01	NE	
Diprophylline, combinations	R03DA51	NE	
Dipyridamole	B01AC07	0	<ul style="list-style-type: none"> • No special advice
Dipyrocetil, combinations with psycholeptics	N02BA79	NE	
Dipyrocetyl	N02BA09	NE	
Dipyrocetyl and corticosteroids	M01BA02	NE	
Dipyrocetyl, combinations excl. Psycholeptics	N02BA59	NE	
Disopyramide	C01BA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Distigmine	N07AA03	NE	
Disulfiram	N07BB01	II	<ul style="list-style-type: none"> Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. Advise the patient to strictly follow the prescribed doses and treatment procedures and to avoid any alcohol or other psychoactive substances during the treatment. Alcohol cessation can also cause behavioural changes and requires follow-up and counselling. Driving with this treatment should require an approval by driving licence administration.
Ditazole	B01AC01	NE	
Dithranol	D05AC01	0	<ul style="list-style-type: none"> No special advice
Dithranol, combinations	D05AC51	0	<ul style="list-style-type: none"> No special advice
Dixyrazine	N05AB01	NE	
Dobutamine	C01CA07	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Docosanol	D06BB11	NE	
Docusate sodium	A06AA02	0	<ul style="list-style-type: none"> No special advice
Docusate sodium, incl. combinations	A06AG10	0	<ul style="list-style-type: none"> No special advice
Dodeclonium bromide, combinations	D08AJ59	NE	
Dofetilide	C01BD04	NE	
Dolasetron	A04AA04	NE	
Domiodol	R05CB08	NE	
Domiphen	A01AB06	NE	
Domperidone	A03FA03	0	<ul style="list-style-type: none"> No special advice
Donepezil	N06DA02	II	<ul style="list-style-type: none"> Inform your patient (and explain his/her caregiver) about the effects of the medication on reaction time as well as that the medication can cause side-effects

			<p>that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.).</p> <ul style="list-style-type: none"> • Advise your patient (and explain his/her caregiver) not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient (and explain his/her caregiver) not to drive because his/her driving skills are still impaired for approximately 24 hours. • Driving with this treatment should require an approval by driving licence administration.
Dopamine	C01CA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Dopexamine	C01CA14	NE	
Dornase alfa (desoxyribonuclease)	R05CB13	0	<ul style="list-style-type: none"> • No special advice
Dorzolamide	S01EC03	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Dosmalfato	A02BX	0	<ul style="list-style-type: none"> • No special advice
Dosulepin	N06AA16	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.

Doxacurium chloride	M03AC07	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Doxapram	R07AB01	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (tremor, clonus, vertigo, dizziness, confusion, pupil dilatation) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Doxazosin	C02CA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Doxefazepam	N05CD12	NE	
Doxepin	N06AA12	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Doxofylline	R03DA11	NE	
Doxycycline	A01AB22	0	<ul style="list-style-type: none"> • No special advice
Doxylamine	R06AA09	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights)

			<ul style="list-style-type: none"> Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Dronabinol	A04AD10	NE	
Droperidol	N01AX01	III	<ul style="list-style-type: none"> Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) Advise the patient to strictly follow the prescribed doses and the intake scheme. Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Droperidol, injectable	N05AD08	III	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol when taking this medicine. In short-term use (eg nausea and vomiting), inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Dropropizine	R05DB19	NE	
Drotaverine	A03AD02	NE	
Drotrecogin alfa (activated)	B01AD10	0	<ul style="list-style-type: none"> No special advice
Droxycam	M01AC04	NE	
Droxypropine	R05DB17	NE	
Duloxetine	N06AX21	II	<ul style="list-style-type: none"> Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). Advise your patient not to drive for the first few weeks of treatment or until the next

			<p>visit and to be careful in other situations, as well (e.g. operating machinery and working at heights).</p> <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Dyclonine	N01BX02 R02AD04	NE	
Dyhydroergotamine, combinations	N02CA51	NE	
E	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Ebastine	R06AX22	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (drowsiness, somnolence) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Econazole	D01AC03	0	<ul style="list-style-type: none"> • No special advice
Ecothiopate	S01EB03	NE	
Edoxudine	D06BB09	NE	
Eflornithine	D11AX16	0	<ul style="list-style-type: none"> • No special advice
Efloxate	C01DX13	NE	
Electrolytes	B05BB01	0	<ul style="list-style-type: none"> • No special advice
Electrolytes in combination with other drugs	B05XA31	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Electrolytes with Carbohydrates	B05BB02	0	<ul style="list-style-type: none"> • No special advice
Eletriptan	N02CC06	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions.

			<ul style="list-style-type: none"> • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Eltrombopag	B02BX05	0	<ul style="list-style-type: none"> • No special advice
Emedastine	S01GX06	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Emepronium and psycholeptics	A03CA30	NE	
Emepronium, combinations	N05CX05	NE	
Emodina	A05AX Not yet determined	NE	
Emylcamate	N05BC03	NE	
Enalapril	C09AA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Enalapril and diuretics	C09BA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Enalapril and lercanidipine	C09BB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Encainide	C01BC08	NE	
Endralazine	C02DB03	NE	
Enflurane	N01AB04	NE	
Enoxaparin	B01AB05	0	<ul style="list-style-type: none"> No special advice
Enoximone	C01CE03	NE	
Enoxolone	D03AX10	NE	
Enprostil	A02BB02	NE	
Entacapone	N04BX02	II	<ul style="list-style-type: none"> Advise the patient (and explain to caregivers) not to drive during the first days of treatment. Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks". Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).
Eosin	D08AX02	NE	
Epanolol	C07AB10	NE	
Eperisone	M03BX09	NE	
Ephedrine	R01AB05	Depending on the medicine in combination	<ul style="list-style-type: none"> Depending on the medicine in combination
Ephedrine	R03CA02	I	<ul style="list-style-type: none"> Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (anxiety, restlessness, insomnia, tremor) Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Ephedrine	S01FB02	NE	
Ephedrine, combinations	A08AA56	NE	

Epinastine	R06AX24	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Epinastine	S01GX10	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Epinephrine	A01AD01 B02BC09	0	<ul style="list-style-type: none"> • No special advice
Epinephrine	C01CA24	I	<p>Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.</p> <p>Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.</p>
Epinephrine	R01AA14 R03AA01 S01EA01	NE	
Epinephrine and other drugs for obstructive airway diseases	R03AK01	NE	
Epinephrine, combinations	S01EA51	NE	
Epitizide and potassium-sparing agents (spironolactone)	C03EA03	NE	
Eplerenone	C03DA04	0	<ul style="list-style-type: none"> • No special advice
Epomediol	A05BA05	NE	
Epoprostenol	B01AC09	0	<ul style="list-style-type: none"> • No special advice
Eprazinone	R05CB04	NE	

Eprosartan	C09CA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Eprosartan and diuretics	C09DA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Eprozinol	R03DX02	NE	
Eptacog alfa (activated)	B02BD08	0	<ul style="list-style-type: none"> • No special advice
Eptifibatide	B01AC16	0	<ul style="list-style-type: none"> • No special advice
Eptotermin alfa	M05BC02	0	<ul style="list-style-type: none"> • No special advice
Erdosteine	R05CB15	0	<ul style="list-style-type: none"> • No special advice
Ergocalciferol (in combinacion, Vitalipid)	A11CC01	0	<ul style="list-style-type: none"> • No special advice
Ergoloid mesylates	C04AE01	NE	
Ergoloid mesylates, combinatiom	C04AE51	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ergotamine	N02CA02	NE	
Ergotamine, combinations	N02CA72	NE	
Ergotamine, combinations excl. psycholeptics	N02CA52	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Eritrityl tetranitrate	C01DA13	NE	
Eritrityl tetranitrate,	C01DA63	NE	

combinations			
Erythrocytes	B05AX01	NE	
Erythromycin	D10AF02	0	<ul style="list-style-type: none"> • No special advice
Erythromycin, combinations	D10AF52	0	<ul style="list-style-type: none"> • No special advice
Erythropoietin (epoetin alfa, beta, theta)	B03XA01	0	<ul style="list-style-type: none"> • No special advice
Erytromycin	S01AA17	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Escitalopram	N06AB10	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Esketamine	N01AX14	NE	
Eslicarbazepine	N03AF04	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Esmolol	C07AB09	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Esomeprazole	A02BC05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair

			his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Esomeprazole, amoxicillin and clarithromycin	A02BD06	NE	
Estazolam	N05CD04	NE	
Eszopiclone	N05CF04	NE (SPC not yet published)	
Etacrynic acid	C03CC01	NE	
Etafenone	C01DX07	NE	
Etallobarbital	N05CA20	NE	
Etamiphylline	R03DA06	NE	
Etamiphylline and adrenergics	R03DB06	NE	
Etamivan	R07AB04	NE	
Etamsylate	B02BX01	0	• No special advice
Etanautine	N04AB01	NE	
Ethacridine lactate	B05CA08 D08AA01	NE	
Ethadione	N03AC03	NE	
Ethanol	D08AX08	0	• No special advice
Ethchlorvynol	N05CM08	NE	
Ethenzamide	N02BA07	NE	
Ethenzamide, combinations excl. Psycholeptics	N02BA57	NE	
Ethenzamide, combinations with psycholeptics	N02BA77	NE	
Ethosuximide combinations	N03AD51	NE	
Ethotoin	N03AB01	NE	
Ethoxusimide	N03AD01	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the

			<p>physician – doctor if he/she should do so.</p> <ul style="list-style-type: none"> Advise the patient not to drink alcohol while taking this medication.
Ethulose	A06AC02	NE	
Ethyl biscoumacetate	B01AA08	NE	
Ethyl chloride	N01BX01	NE	
Ethyl hydroxybenzoate	D01AE10	NE	
Ethyl loflazepate	N05BA18	NE	
Ethylestrenol	A14AB02	NE	
Ethylmorphine	R05DA01	III	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness) Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Ethylmorphine	S01XA06	NE	
Etidocain combinations	N01BB57	NE	
Etidocaine	N01BB07	NE	
Etidronic acid	M05BA01	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. somnolence, dizziness vertigo or ataxia), and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Etidronic acid and calcium, sequential	M05BB01	NE	
Etifoxine	N05BX03	NE	
Etilamfetamine	A08AA06	NE	
Etilefrine	C01CA01	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Etilefrine, combinations	C01CA51	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Etilevodopa and decarboxylase inhibitor	N04BA06	NE	
Etizolam	N05BA19	NE	
Etodolac	M01AB08	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Etofenamate	M02AA06	0	• No special advice
Etofibrate	C10AB09	NE	
Etofylline nicotinate	C04AD04	NE	
Etomidate	N01AX07	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Etoferidone	N06AB09	NE	
Etoricoxib	M01AH05	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.

Etozolin	C03CX01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Etretinate	D05BB01	NE	
Etybenzatropine	N04AC30	NE	
Euflavine	D08AA03	NE	
Exenatide	A10BX04	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Ezetimibe	C10AX09	0	<ul style="list-style-type: none"> • No special advice
F	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Factor VIII inhibitor bypassing activity	B02BD03	0	<ul style="list-style-type: none"> • No special advice
Famciclovir	S01AD07	NE	
Famotidine	A02BA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Famotidine, combinations	A02BA53	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Fasudil	C04AX32	NE	
Fat emulsions	B05BA02	NE	
Fazadinium bromide	M03AC08	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed.

			<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Febarbamate	M03BA05	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Febuxostat	M04AA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. somnolence, dizziness vertigo or ataxia), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Fedrilate	R05DB14	NE	
Felbamate	N03AX10	NE	
Felbinac	M02AA08	0	<ul style="list-style-type: none"> • No special advice
Felodipine	C08CA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Femoxetine	N06AB Not yet determined	NE	
Fenazocine	N02AD02	NE	
Fenbufen	M01AE05	NE	
Fencamfamin	N06BA06	NE	
Fendiline	C08EA01	NE	
Fenetylline	N06BA10	NE	

Fenfluramine	A08AA02	NE	
Fenofibrate	C10AB05	0	• No special advice
Fenoldopam	C01CA19	NE	
Fenoprofen	M01AE04 N02BG	NE	
Fenoterol	R03AC04	0	• No special advice
Fenoterol	R03CC04	NE	
Fenoterol and other drugs for obstructive airway diseases	R03AK03	NE	
Fenoverine	A03AX05	NE	
Fenoxazoline	R01AA12	NE	
Fenozolone	N06BA08	NE	
Fenpiprane	A03AX01	NE	
Fenpiverinium	A03AB21	NE	
Fenproporex	N06BA	NE	
Fenquizone	C03BA13	NE	
Fenspiride	R03BX01 R03DX03	NE	
Fentanyl - Oral administration - Parenteral administration - Transdermal administration	N01AH01 N02AB03	III III III/II* *) prolonged release formulation; when a steady state of dosage has been reached	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Fentanyl combinations	N01AH51	NE	
Fentiazac	M01AB10 M02AA14	NE	
Fenticonazole	D01AC12	0	• No special advice

Fentonium	A03BB04	NE	
Fenylramidol	M03BX30	NE	
Feprazone	M01AX18 M02AA16	NE	
Feprazone, combinations	M01AX68	NE	
Ferric acetyl transferrin	B03AB08	NE	
Ferric citrate	B03AB06	0	• No special advice
Ferric hydroxide	B03AB04	0	• No special advice
Ferric oxide dextran complex	B03AC06	0	• No special advice
Ferric proteinsuccinylate	B03AB09	0	• No special advice
Ferric sodium citrate	B03AB01	NE	
Ferric sodium gluconate complex	B03AC07	NE	
Ferric sorbitol gluconic acid complex	B03AC05	NE	
Ferrous amino acid complex	B03AD01	0	• No special advice
Ferrous ascorbate	B03AA10	NE	
Ferrous aspartate	B03AA09	NE	
Ferrous carbonate	B03AA04	NE	
Ferrous chloride	B03AA05	NE	
Ferrous fumarate	B03AA02 B03AD02	0	• No special advice
Ferrous gluconate	B03AA03	0	• No special advice
Ferrous glycine sulfate	B03AA01	0	• No special advice
Ferrous iodine	B03AA11	NE	
Ferrous succinate	B03AA06	NE	
Ferrous sulfate	B03AA07 B03AD03	0	• No special advice
Ferrous tartrate	B03AA08	NE	
Fexofenadine	R06AX26	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive when this side effects occur and also to be careful in

			<p>other situations (e.g. using machinery and working at heights)</p> <ul style="list-style-type: none"> • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Fibrinogen, human	B02BC10	0	<ul style="list-style-type: none"> • No special advice
Fibrinolysin	B01AD05	NE	
Fibrinolysin and desoxyribonuclease	B06AA02	NE	
Finasteride	D11AX10	0	
Fipexide	N06BX05	NE	
Flecainide	C01BC04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Floctafenine	N02BG04	NE	
Flurometholone and antiinfectives - Drops - Ointment	S01CA07	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Fluanisone	N05AD09	NE	
Flubiprofen	S01BC04	NE	
Fluclorolone	D07AC02	0	<ul style="list-style-type: none"> • No special advice
Fluconazole	D01AC15	NE	
Flucytosine	D01AE21	NE	
Fludiazepam	N05BA17	NE	
Fludrocortisone and antiinfectives - Drops - Ointment	S01CA06	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Fludrocortisone and antiinfectives	S02CA07 S03CA05	0	<ul style="list-style-type: none"> • No special advice
Fludroxycortide	D07AC07	NE	
Fludroxycortide and antibiotics	D07CC03	NE	

Flufenamic acid	M01AG03	NE	
Flumetasone	D07AB03 D07XB01	0	<ul style="list-style-type: none"> • No special advice
Flumetasone and antibiotics	D07CB05	NE	
Flumetasone and antiinfectives	S02CA02	NE	
Flumetasone and antiseptics	D07BB01	0	<ul style="list-style-type: none"> • No special advice
Flunarizine	N07CA03	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • The treatment has to be used according to the recommended dose. • Vertigo and hearing loss requiring this treatment can also impair ability to drive.
Flunisolide	R03BA03	NE	
Flunitrazepam	N05CD03	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Flunoxaprofen	M01AE15	NE	
Fluocinolone acetonide	C05AA10 D07AC04	0	<ul style="list-style-type: none"> • No special advice
Fluocinolone acetonide	S01BA15 S02BA08	NE	
Fluocinolone acetonide and antibiotics	D07CC02	0	<ul style="list-style-type: none"> • No special advice
Fluocinolone acetonide and antiinfectives	S01CA10	NE	
Fluocinolone acetonide and antiinfectives	S02CA05	0	<ul style="list-style-type: none"> • No special advice
Fluocinolone acetonide and	D07BC02	0	<ul style="list-style-type: none"> • No special advice

antiseptics			
Fluocinonide	C05AA11 D07AC08	0	• No special advice
Fluocinonide and antibiotics	D07CC05	0	• No special advice
Fluocortin	D07AB04	0	• No special advice
Fluocortolone	C05AA08	NE	
Fluocortolone	D07AC05	0	• No special advice
Fluocortolone and antibiotics	D07CC06	NE	
Fluocortolone and antiinfectives	S01CA04	NE	
Fluocortolone and antiseptics	D07BC03	0	• No special advice
Fluorescein	S01JA01	0	• No special advice
Fluorescein, combinations	S01JA51	Depending on the medicine in combination	• Depending on the medicine in combination (Fluorescein + local anaesthetics cat I)
Fluoride, combinations	A12CD51	0	• No special advice
Fluorocarbon blood substitutes	B05AA03	NE	
Fluorometholone	C05AA06 D07XB04	0	• No special advice
Fluorometholone - Drops - Ointment	S01BA07	0 I	• Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advice the patient that he/she should wait until his/her vision clears before driving or using machinery.
Fluorometholone	D07AB06 D10AA01	NE	
Fluorometholone	S01CB05	Depending on the mydriatic in combination	• Depending on the mydriatic in combination
Fluorometholone and antibiotics	D07CB03	NE	
Fluorometholone and mydriatics	S01BB03	Depending on the mydriatic in combination	• Depending on the mydriatic in combination

Fluostigmine	S01EB07	NE	
Fluoxetine	N06AB03	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Flupentixol - Oral administration	N05AF01	II	<p>Oral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
- Parenteral administration: depot i.m.		III	<p>Parenteral administration</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Fluperolone	D07AB05	NE	
Fluphenazine: injection depot i.m.	N05AB02	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit

			<p>after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights)</p> <ul style="list-style-type: none"> • Advise the patient not to drink alcohol when taking this medicine.
Flupirtine	N02BG07	NE	
Fluprednidene	D07AB07 D07XB03	NE	
Fluprednidene and antibiotics	D07CB02	NE	
Flurazepam	N05CD01	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time(occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Flurbiprofen	M01AE09	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Flurbiprofen	M02AA19 R02AX01	0	<ul style="list-style-type: none"> • No special advice
Fluspirilene: injection i.m.	N05AG01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Fluticasone	D07AC17 R01AD08	0	<ul style="list-style-type: none"> • No special advice • No special advice

	R03BA05		• No special advice
Fluticasone furoate	R01AD12	0	• No special advice
Flutrimazole	D01AC16	0	• No special advice
Fluvastatin	C10AA04	0	• No special advice
Fluvoxamine	N06AB08	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Folic acid	B03BB01	0	• No special advice
Folic acid, combinations	B03BB51	0	• No special advice
Fomivirsen	S01AD08	NE	
Fondaparinux	B01AX05	0	• No special advice
Formocortal	S01BA12	NE	
Formoterol	R03AC13	0	• No special advice
Formoterol and other drugs for obstructive airway diseases	R03AK07	NE	
Fosaprepitant	A04AD	0	• No special advice
Fosinopril	C09AA09	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Fosinopril and diuretics	C09BA09	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Fosphenytoin	N03AB05	NE	
Framycetin	D09AA01	NE	

	R01AX08 S01AA07		
Frovatriptan	N02CC07	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Fructose 1,6-diphosphate	C01EB07	NE	
Fumaric acid	D05AX01	NE	
Fumaric acid derivatives, combinations	D05BX51	NE	
Funisolid	R01AD04	0	• No special advice
Furosemide	C03CA01	0	• No special advice
Furosemide and potassium	C03CB01	0	• No special advice
Furosemide and potassium-sparing agents	C03EB01	0	• No special advice
Fusafungine	R02AB03	NE	
Fusidic acid	D06AX01 D09AA02	0	• No special advice
Fusidic acid - Drops - Ointment	S01AA13	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Gabapentin	N03AX12	II	Advise the patient not to drive during the first days of treatment as well as after dose increases.

			<p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication. <p>Neuropathic pain.</p> <ul style="list-style-type: none"> • Advise the patient not to drive during the first days of treatment as well as after dose increases.
Galantamine	N06DA04	II	<ul style="list-style-type: none"> • Inform your patient (and explain his/her caregiver) about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient (and explain his/her caregiver) not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient (and explain his/her caregiver) not to drive because his/her driving skills are still impaired for approximately 24 hours. • Driving with this treatment should require an approval by driving licence administration.
Gallamine	M03AC02	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Gallopamil	C08DA02	NE	
Galsulfase	A16AB08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Gamolonic acid, combinations	D11AX52	NE	

Ganciclovir	S01AD09	0	• No special advice
Gatifloxacin	S01AX21	NE	
Gedocarnil	N05BX02	NE	
Gefarnate	A02BX07	NE	
Gefarnate, combinations with psycholeptics	A02BX77	NE	
Gelatin agents	B05AA06	0	• No special advice
Gemfibrozil	C10AB04	0	• No special advice
Gentamicin	D06AX07	0	• No special advice
Gentamicin - Drops - Ointment	S01AA11	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Gentamicin	S02AA14 S03AA06	NE	
Gepefrine	C01CA15	NE	
Gepirone	N06AX19	NE	
Ginkgo Biloba	N06DX02	0	• No special advice
Gitoformate	C01AA09	NE	
Glafenine	N02BG03	NE	
Glibenclamide	A10BB01	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Glibornuride	A10BB04	NE	
Gliclazide	A10BB09	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise

			hypoglycaemia. The advisability of driving should be considered in these circumstances. <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Glimepiride	A10BB12	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Glimepiride and pioglitazone	A10BD06	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Glimepiride and rosiglitazone	A10BD04	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Glipizide	A10BB07	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Gliquidone	A10BB08	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Glisoxepide	A10BB11	NE	
Glucosamine	M01AX05	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Glucosaminoglykan polysulfate	M01AX12	NE	
Glucose	B05CX01	0	<ul style="list-style-type: none"> • No special advice
Glucose, combinations	C05BB56	0	<ul style="list-style-type: none"> • No special advice
Glutamic acid hydrochloride	A09AB01	NE	
Glutamine	A16AA03	0	<ul style="list-style-type: none"> • No special advice
Glutethimide	N05CE01	NE	
Glycerol	A06AG04 A06AX01	0	<ul style="list-style-type: none"> • No special advice
Glyceryl trinitrate	C01DA02 C05AE01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Glyceryl trinitrate, combinations.	C01DA52	NE	
Glycine	B05CX03	0	<ul style="list-style-type: none"> • No special advice

Glycopyrronium	A03AB02	0	• No special advice
Glycopyrronium and psycholeptics	A03CA05	NE	
Glycyrrhizic acid	A05BA08	NE	
Glymidine	A10BC01	NE	
Gramicidin	R02AB30	NE	
Granisetron	A04AA02	0	• No special advice
Griseofulvin	D01AA08	NE	
Griseofulvin	D01BA01	0	• No special advice
G-strophanthin	C01AC01	NE	
Guacetasal	N02BA14	NE	
Guaiacolsulfonate	R05CA09	NE	
Guaiazulen	S01XA01	NE	
Guaifenesin	R05CA03	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Guanazodine	C02CC06	NE	
Guanethidine	C02CC02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Guanethidine	S01EX01	NE	
Guanethidine and diuretics	C02LF01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Guanfacine	C02AC02	II	• Inform your patient that the medication can cause side effects that impair driving

			<p>abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.).</p> <ul style="list-style-type: none"> • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Guanoclor	C02CC05	NE	
Guanoxabenz	C02CC07	NE	
Guanoxan	C02CC03	NE	
Guar gum	A10BX01	0	<ul style="list-style-type: none"> • No special advice
H	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Hachimycin	D01AA03	NE	
Halazepam	N05BA13	NE	
Halcinonide	D07AD02	NE	
Halometasone	D07AC12	0	<ul style="list-style-type: none"> • No special advice
Haloperidol - Oral administration	N05AD01	II	<p>Oral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use (eg intractable hiccup, nausea and vomiting), inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
- Parenteral administration:i.v./i.m.		III	<p>Parenteral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights)

			<ul style="list-style-type: none"> • Advise the patient not to drink alcohol when taking this medicine. • In short-term use (eg intractable hiccup, nausea and vomiting), inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Haloproglin	D01AE11	NE	
Halothane	N01AB01	NE	
Hematin	B06AB01	0	<ul style="list-style-type: none"> • No special advice
Hemoglobin crosumaril	B05AA08	NE	
Hemoglobin glutamer (bovine)	B05AA10	NE	
Hemoglobin raffimer	B05AA09	NE	
Heparin	B01AB01 C05BA03	0	<ul style="list-style-type: none"> • No special advice
Heparin	S01XA14	NE	
Heparin, combinations	B01AB51	NE	
Heparin, combinations	C05BA53	0	<ul style="list-style-type: none"> • No special advice
Heparinoid, combinations	C05BA51	0	<ul style="list-style-type: none"> • No special advice
Heptabarbital	N05CA11	NE	
Heptaminol	C01DX08	NE	
Hexachlorophene	D08AE01	NE	
Hexafluronium	M03AC05	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Hexamidine	D08AC04 R01AX07 R02AA18 S01AX08 S03AA05	NE	
Hexapropymate	N05CM10	NE	
Hexetidine	A01AB12	0	<ul style="list-style-type: none"> • No special advice
Hexobarbital	N01AF02 N05CA16	NE	
Hexobendine	C01DX06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair

			his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Hexocyclium	A03AB10	NE	
Hexoprenaline	R03AC06 R03CC05	NE	
Hexylresorcinol	R02AA12	0	<ul style="list-style-type: none"> No special advice
Hidrosmin	C05CA05	0	<ul style="list-style-type: none"> No special advice
Histapyrrodine	R06AC02	II	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Histapyrrodine, combinations	R06AC52	NE	
Homatropine	S01FA05	III	<ul style="list-style-type: none"> Inform the patient that this ocular medication may cause transient blurring of vision or that he/she may suffer from photophobia and that this may impair their ability to drive under certain circumstances. Complete recovery from the effects of mydriatic anticholinergics may take up to 24 hours. Advise the patients not to drive or operate hazardous machinery until 24 hours after receiving ocular medication (recovery occurs within 24 hours) or until vision is clear.
Human fibrinogen	B02BB01	0	<ul style="list-style-type: none"> No special advice
Human fibrinogen / Human thrombin (Evicel®)	B02BC	0	<ul style="list-style-type: none"> No special advice
Hyaluronic acid	R01AX09 S01KA01 D03AX05	NE	
Hyaluronic acid	M09AX01	0	<ul style="list-style-type: none"> No special advice
Hyaluronic acid, combinations	S01KA51	NE	
Hyaluronidase	B06AA03	0	<ul style="list-style-type: none"> No special advice

Hydralazine	C02DB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Hydralazine and diuretics	C02LG02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Hydrixybutiric acid	N01AX11	NE	
Hydrochloric acid	A09AB03	NE	
Hydrochloric acid	B05XA13	0	<ul style="list-style-type: none"> • No special advice
Hydrochlorothiazide	C03AA03	0	<ul style="list-style-type: none"> • No special advice
Hydrochlorothiazide and potassium	C03AB03	0	<ul style="list-style-type: none"> • No special advice
Hydrochlorothiazide and potassium-sparing agents (spironolactone)	C03EA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Hydrochlorothiazide, combinations	C03AX01	0	<ul style="list-style-type: none"> • No special advice
Hydrocodone	R05DA03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Hydrocortisone	A01AC03 A07EA02 C05AA01	0	<ul style="list-style-type: none"> • No special advice

	D07AA02 D07XA01		
Hydrocortisone	S01BA02	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Hydrocortisone (with mydriatics)	S01CB03	Depending on the mydriatic in combination	<ul style="list-style-type: none"> • Depending on the mydriatic in combination
Hydrocortisone	S02BA01	NE	
Hydrocortisone aceponate	D07AC16	NE	
Hydrocortisone and antibiotics	D07CA01	0	<ul style="list-style-type: none"> • No special advice
Hydrocortisone and antiinfectives - Drops - Ointment	S01CA03	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Hydrocortisone and antiinfectives	S02CA03	0	<ul style="list-style-type: none"> • No special advice
Hydrocortisone and antiinfectives	S03CA04	0	<ul style="list-style-type: none"> • No special advice
Hydrocortisone and antiseptics	D07BA04	0	<ul style="list-style-type: none"> • No special advice
Hydrocortisone and mydriatics	S01BB01	Depending on the mydriatic in combination	<ul style="list-style-type: none"> • Depending on the mydriatic in combination
Hydrocortisone buteprate	D07AB11	NE	
Hydrocortisone butyrate	D07AB02	0	<ul style="list-style-type: none"> • No special advice
Hydrocortisone butyrate and antiseptics	D07BB04	NE	
Hydrocortisone, combinations	R01AD60	NE	
Hydroflumethiazide	C03AA02	0	<ul style="list-style-type: none"> • No special advice
Hydroflumethiazide and potassium	C03AB02	0	<ul style="list-style-type: none"> • No special advice
Hydroflumethiazide,	C03AH02	NE	

combinations			
Hydrogen peroxide	A01AB02 D08AX01	0	• No special advice
Hydrogen peroxide	S02AA06	NE	NE
Hydromorphone	N02AA03	III/II* *) prolonged release formulation; when a steady state of dosage has been reached	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Hydromorphone and antispasmodics	N02AG04	NE	
Hydroquinidine	C01BA	NE	
Hydroquinine	M09AA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. visual disturbances, vertigo), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Hydroquinone	D11AX11	0	• No special advice
Hydrotalcite	A02AD04	0	• No special advice
Hydroxocobalamin	B03BA03	0	• No special advice
Hydroxocobalamin, combinations	B03BA53	0	• No special advice
Hydroxybutyric acid	N07XX04	NE	
Hydroxyethylpromethazine	R06AD05	NE	
Hydroxyethylpromethazine, combinations	R06AD55	NE	
Hydroxyethylstarch	B05AA07	0	• No special advice

Hydroxyzine	N05BB01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for a few days. Advise your patient not to drive then.
Hydroxyzine, combinations	N05BB51	NE	
Hymecromone	A05AX02	NE	
Hyoscyamine	A03BA03	NE	
Hyoscyamine and Psycholeptics	A03CB31	NE	
Hypericine	N06AX20	0	<ul style="list-style-type: none"> • No special advice
Hypertonic solutions	B05DB	0	<ul style="list-style-type: none"> • No special advice
Hypromellose	S01KA02	0	<ul style="list-style-type: none"> • No special advice
	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Ibandronic acid	M05BA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. headache, dizziness, and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Ibopamine	C01CA16 S01FB03	NE	
Ibudilast	R03DC04	NE	
Ibuprofen	C01EB16	NE	
Ibuprofen	M02AA13	0	<ul style="list-style-type: none"> • No special advice
Ibuprofen	M01AE01 N02BG	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects.

			<ul style="list-style-type: none"> • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Ibuprofen, combinations	M01AE51	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Ibuproxam	M01AE13	NE	
Ibutilide	C01BD05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Icatibant	C01EB19	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ichtasol	D10BX01	NE	
Idanpramine	A03AX06	NE	
Idebenone	N06BX13	NE	
Idoxuridine	D06BB01	0	<ul style="list-style-type: none"> • No special advice
Idoxuridine	S01AD01	NE	
Idursulfase	A16AB09	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Ifenprodil	C04AX28	NE	
Iloprost (for inhalation use)	B01AC11	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (down blood pressure and may cause dizziness or light-headedness). Do

			<p>not drive or operate any tools or machines if you feel these effects of low blood pressure.</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment until any effects on the individual have been determined and also to be careful in other situations (e.g. using machinery and working at heights)
Imidapril	C09AA16	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Imidazole salicylate	N02BA16	NE	
Imiglucerase	A16AB02	0	<ul style="list-style-type: none"> • No special advice
Imipramine	N06AA02	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Imipramine oxide	N06AA03	NE	
Imiquimod	D06BB10	0	<ul style="list-style-type: none"> • No special advice
Imolamine	C01DX09	NE	
Indacaterol	R03AC18	0	<ul style="list-style-type: none"> • No special advice
Indalpine	N06AB Not yet determined	NE	
Indapamide	C03BA11	0	<ul style="list-style-type: none"> • No special advice
Indobufen	B01AC10	NE	
Indometacin	C01EB03 S01BC01	NE	

Indometacin	M01AB01	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Indometacin	M02AA23	0	<ul style="list-style-type: none"> • No special advice
Indometacin, combinations	M01AB51	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Indoprofen	M01AE10	NE	
Indoramin	C02CA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Inosine	D06BB05	0	<ul style="list-style-type: none"> • No special advice
Inosine	S01XA10	NE	
Inositol	A11HA07	0	<ul style="list-style-type: none"> • No special advice
Inositol nicotinate	C04AC03	0	<ul style="list-style-type: none"> • No special advice
Insulins and analogues	A10AB A10AC A10AD A10AE A10AF	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient have frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Interferon	S01AD05	NE	
Invert sugar	C05BB03	0	<ul style="list-style-type: none"> • No special advice

Iodine	D08AG03	0	• No special advice
Iodine/octylphenoxypolyglycol ether	D08AG01	NE	
Iodoform	D09AA13	NE	
Iodoheparinate	S01XA09	NE	
Ipecacuanha	R05CA04	0	• No special advice
Ipratropium bromide	R01AX03	0	• No special advice
Ipratropium bromide	R03BB01	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, blurred vision) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Iprazochrome	N02CX03	NE	
Ipriflavone	M05BX01	NE	
Iprindole	N06AA13	NE	
Iproclozide	N06AF06	NE	
Iproniazide	N06AF05	NE	
Irbesartan	C09CA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Irbesartan and diuretics	C09DA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Iron and multivitamins	B03AE03	0	• No special advice
Iron, multivitamins and folic acid	B03AE02	0	• No special advice
Iron, multivitamins and	B03AE04	0	• No special advice

minerals			
Iron, vitamin B12 and folic acid	B03AE01	0	• No special advice
Iron-sorbitol-citric acid complex	B03AC03	NE	
Isoaminile	R05DB04	NE	
Isobromindione	M04AB04	NE	
Isocarboxazide	N06AF01	NE	
Isoconazole	D01AC05	NE	
Isoetarine	R03AC07 R03CC06	NE	
Isoflurane	N01AB06	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Isometheptene	A03AX10	0	• No special advice
Isoprenaline	C01CA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Isoprenaline	R03AB02 R03CB01	NE	
Isoprenaline and other drugs for obstructive airway diseases	R03AK02	NE	
Isoprenaline, combinations	R03CB51	NE	
Isopropamide	A03AB09	NE	

Isopropamide and psycholeptics	A03CA01	NE	
Isopropanol	D08AX05	NE	
Isosorbide dinitrate	C01DA08 C05AE02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Isosorbide dinitrate, combinations	C01DA58	NE	
Isosorbide mononitrate	C01DA14	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Isothipendyl	D04AA22	NE	
Isothipendyl	R06AD09	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Isotonic solutions	B05DA	0	<ul style="list-style-type: none"> • No special advice
Isotretinoin	D10AD04	0	<ul style="list-style-type: none"> • No special advice
Isotretinoin - Oral administration - Topical use	D10BA01	II 0	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g., decreased night vision in some cases was sudden, visual and neurological disturbances etc.) • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.

Isotretinoin, combinations (with erythromycin, topical use)	D10AD54	0	• No special advice
Isoxsuprine	C04AA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ispaghula (psylla seeds)	A06AC01	0	• No special advice
Ispaghula, combinations	A06AC51	0	• No special advice
Isradipine	C08CA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Itramin tosilate	C01DX01	NE	
Itramin tosilate, combinations	C01DX51	NE	
Ivabradine	C01EB17	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
K	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Kallidinogenase	C04AF01	NE	
Kanamycin	A07AA08 S01AA24	NE	
Kaolin	A07BC02	NE	
Kebuzone	M01AA06	NE	
Ketamine	N01AX03	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage.

			<ul style="list-style-type: none"> • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Ketanserin	C02KD01	NE	
Ketazolam	N05BA10	NE	
Ketobemidone	N02AB01	NE	
Ketobemidone and antispasmodics	N02AG02	NE	
Ketoconazole	D01AC08	0	<ul style="list-style-type: none"> • No special advice
Ketoprofen	M02AA10	0	<ul style="list-style-type: none"> • No special advice
Ketoprofen	M01AE03 N02BG	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Ketoprofen, combinations	M01AE53	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Ketorolac	M01AB15	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Ketorolac	S01BC05	0	<ul style="list-style-type: none"> • No special advice

Ketotifen	R06AX17	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, insomnia) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Ketotifen	S01GX08	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
L	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Labetalol	C07AG01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Labetalol and other diuretics	C07CG01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Labetalol and thiazides	C07BG01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Lacidipine	C08CA09	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Lacosamide	N03AX18	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> Advise the patient to take the medicine as prescribed by the physician. Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. Advise the patient not to drink alcohol while taking this medication.
Lactic acid producing organisms	A07FA01	0	<ul style="list-style-type: none"> No special advice
Lactic acid producing organisms, combinations	A07FA02	0	<ul style="list-style-type: none"> No special advice
Lactitol	A06AD12	0	<ul style="list-style-type: none"> No special advice
Lactulose	A06AD11	0	<ul style="list-style-type: none"> No special advice
Lactulose, combinations	A06AD61	NE	
Lafutidine	A02BA08	NE	
Lamotrigine	N03AX09	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>Advise the patient that visual field testing should be done regularly.</p> <p>General warnings:</p> <ul style="list-style-type: none"> Advise the patient to take the medicine as prescribed by the physician. Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. Advise the patient not to drink alcohol while taking this medication.
Lanatoside C	C01AA06	NE	
Lansoprazole	A02BC03	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Lansoprazole, amoxicillin and clarithromycin	A02BD07	NE	

Lansoprazole, amoxicillin and metronidazole	A02BD03	NE	
Lansoprazole, tetracycline and metronidazole	A02BD02	NE	
Laronidase	A16AB05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Latanoprost	S01EE01	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Laurilsulfate, incl. combinations	A06AG11	0	<ul style="list-style-type: none"> • No special advice
Lepirudin	B01AE02	0	<ul style="list-style-type: none"> • No special advice
Lercanidipine	C08CA13	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Letosteine	R05CB09	NE	
Levacetylmethadol	N07BC03	NE	
Levetiracetam	N03AX14	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Levobunolol	S01ED03	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or

			using machinery.
Levobupivacaine	N01BB10	0	Categorization, labelling and information to the patient depending of the route of administration
		I	<p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics.
		II	<p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
		III	
Levocabastine	R01AC02	0	<ul style="list-style-type: none"> • No special advice
Levocabastine	S01GX02	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Levocarnitine	A16AA01	0	<ul style="list-style-type: none"> • No special advice
Levocetirizine	R06AE09	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, fatigue, reduced alertness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights)

			<ul style="list-style-type: none"> • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Levodopa	N04BA01	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Levodopa and decarboxylase inhibitor Levodopa+carbidopa Levodopa+benserazide	N04BA02	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Levodopa, decarboxylase inhibitor and COMT inhibitor Levodopa+carbidopa+entacapone	N04BA03	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Levodropropizine	R05DB27	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (fatigue, asthenia, numbness, drowsiness, dizziness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.

Levofloxacin	S01AX19	NE	
Levomepromazine - Oral administration: - Parenteral administration	N05AA02	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Levoprenbutolol	Not yet determined	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Levorphanol	N02AF	NE	
Levosimendan	C01CX08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Levosulpiride	N05AL07 A04AD	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness). • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights). • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Levoverbenone	R05CA11	NE	
Lidocaine	S01HA07 S02DA01	NE	
Lidocaine (Anesthetics, local)	N01BB02	0	Categorization, labelling and information to the patient depending of the route of administration

		I II III	<p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
lidocaine	C05AD01 D04AB01 R02AD02	0	<ul style="list-style-type: none"> • No special advice
Lidocaine (Antiarrhythmics, parenteral use)	C01BB01	I	<p>Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.</p> <p>Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.</p>
Lidocaine, combinations (Anesthetics, local)	N01BB52	0	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p>

		I	<ul style="list-style-type: none"> Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed.
		II	<p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> Advise the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia).</p> <p><u>Spinal /Epidural</u></p>
		III	<ul style="list-style-type: none"> Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Lidoflazine	C08EX01	NE	
Linopirdine	N06BX09	NE	
Linseed	A06AC05	0	<ul style="list-style-type: none"> No special advice
Linseed, combinations	A06AC55	NE	
Linsidomine	C01DX18	NE	
Liquid paraffin	A06AA01	0	<ul style="list-style-type: none"> No special advice
Liquid paraffin, combinations	A06AA51	0	<ul style="list-style-type: none"> No special advice
Liquid plaster	D02AD	0	<ul style="list-style-type: none"> No special advice
Liraglutide	A10BX07	I	<ul style="list-style-type: none"> Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Lisinopril	C09AA03	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Lisinopril and amlodipine	C09BB03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Lisinopril and diuretics	C09BA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Lisuride	N02CA07 G02CB02	NE	
Lithium	N05AN01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Lithium succinate	D11AX04	NE	
Lodoxamide	S01GX05	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Lofepramine	N06AA07	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance

			<p>when taking this medication.</p> <ul style="list-style-type: none"> • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Lofexidine	N07BC04	NE	
Lomefloxacin - Drops - Ointment	S01AX17	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Lomoxicam	M01AC05	NE	
Lonazolac	M01AB09	NE	
Loperamide	A07DA03	0	<ul style="list-style-type: none"> • No special advice
Loperamide oxide	A07DA05	NE	<ul style="list-style-type: none"> • No special advice
Loperamide, combinations	A07DA53	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Loprazolam	N05CD11	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days. Advise your patient not to drive then.
Lorajmine	C01BA12	NE	
Loratadine	R06AX13	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (somnolence, insomnia, drowsiness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.

Lorazepam	N05BA06	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days. Advise your patient not to drive then.
Lorazepam, combinations	N05BA56	NE	
Lorcainide	C01BC07	NE	
Lormetazepam	N05CD06	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Losartan	C09CA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Losartan and diuretics	C09DA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Loteprednol	S01BA14	NE	
Lovastatin	C10AA02	0	<ul style="list-style-type: none"> • No special advice
Lovastatin and nicotinic acid	C10BA01	0	<ul style="list-style-type: none"> • No special advice

Loxapine	N05AH01	NE	
Lubiprostone	A06AX03	NE	
Lumiracoxib	M01AH06	NE	
Lysine	B05XB03	NE	
Lysozyme	D06BB07	0	• No special advice
M	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Macrogol	A06AD15	0	• No special advice
Macrogol, combinations	A06AD65	0	• No special advice
Mafenide	D06BA03	NE	
Magaldrate	A02AD02	0	• No special advice
Magaldrate and antifatulents	A02AF01	0	• No special advice
Magnesium (different salts in combination)	A12CC30	0	• No special advice
Magnesium aspartate	A12CC05	NE	
Magnesium carbonate	A02AA01	0	• No special advice
Magnesium carbonate	A06AD01	NE	
Magnesium chloride	A12CC01 B05XA11	0	• No special advice
Magnesium citrate	A06AD19 A12CC04 B05CB03	NE	
Magnesium gluconate	A12CC03	NE	
Magnesium hydroxide	A02AA04	0	• No special advice
Magnesium lactate	A12CC06	0	• No special advice
Magnesium levulinate	A12CC07	NE	
Magnesium orotate	A12CC09	NE	
Magnesium oxide	A06AD02	NE	
Magnesium oxide	A12CC10	0	• No special advice
Magnesium peroxide	A02AA03 A06AD03	NE	
Magnesium phosphate	B05XA10	0	• No special advice

Magnesium pidolate	A12CC08	0	• No special advice
Magnesium pyridoxal 5-phosphate glutamate	C10AX07	NE	
Magnesium silicate	A02AA05	0	• No special advice
Magnesium sulfate	A06AD04 B05XA05	NE	
Magnesium sulfate	A12CC02 D11AX05	NE	
Mandelic acid	B05CA06	NE	
Manidipine	C08CA11	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Mannitol	A06AD16	NE	
Mannitol	B05BC01 B05CX04	0	<ul style="list-style-type: none"> • No special advice • No special advice
Maprotiline - Oral administration. - Parenteral administration	N06AA21	II III	Oral administration <ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours. Parenteral administration <ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other

			<p>situations, as well (e.g. operating machinery and working at heights).</p> <ul style="list-style-type: none"> • Advice your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advice your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Mazaticol	N04AA10	NE	
Mazindol	A08AA05	NE	
Mebeverine	A03AA04	0	<ul style="list-style-type: none"> • No special advice
Mebhydrolin	R06AX15	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, insomnia) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Mebutamate	N05BC04	NE	
Mebutizide	C03AA13	NE	
Mebutizide and potassium-sparing agents (spironolactone)	C03EA05	NE	
Meclocycline	D10AF04	0	<ul style="list-style-type: none"> • No special advice
Meclofenamic acid	M01AG04 M02AA18	NE	
Meclofenoxate	N06BX01	NE	
Meclozine	R06AE05	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Meclozine, combinations	R06AE55	NE	

Mecobalamin	B03BA05	NE	
Medazepam	N05BA03	NE	
Medicinal charcoal	A07BA01	0	<ul style="list-style-type: none"> • No special advice
Medicinal charcoal, combinations	A07BA51	0	<ul style="list-style-type: none"> • No special advice
Medifoxamine	N06AX13	NE	
Medrysone	S01BA08	NE	
Mefenamic Acid	M01AG01 N02BG	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Mefenorex	A08AA09	NE	
Mefruside	C03BA05	NE	
Mefruside and potassium	C03BB05	NE	
Meglutol	C10AX05	NE	
Melagatran	B01AE04	NE	
Melatonin	N05CH01	I	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first 12 hours after taking the medicine and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Melevodopa	N04BA04	NE	
Melevodopa and decarboxylase inhibitor	N04BA05	NE	
Melitracen	N06AA14	NE	
Melitracen and psycholeptics	N06AC02	NE	
Meloxicam	M01AC06	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects.

			<ul style="list-style-type: none"> • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Melperone	N05AD03	NE	
Memantine	N06DX01	II	<ul style="list-style-type: none"> • Inform your patient (and explain his/her caregiver) about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient (and explain his/her caregiver) not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient (and explain his/her caregiver) not to drive because his/her driving skills are still impaired for approximately 24 hours. • Driving with this treatment should require an approval by driving licence administration.
Menadione	B02BA02	0	<ul style="list-style-type: none"> • No special advice
Mepartricin	A01AB16 D01AA06	NE	
Mepenzolate	A03AB12	NE	
Mephenesin	M03BX06	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Mephenoqualone	N05BX01	NE	

Mephentermine	C01CA11	NE	
Mephenytoin	N03AB04	NE	
Mephenytoin, combinations	N03AB54	NE	
Mepivacaine	N01BB03	0 I II III	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Mepivacaine combinations	N01BB53	0 I	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed.

		II	<p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia).</p> <p><u>Spinal /Epidural</u></p>
		III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Mepixanox	R07AB09	NE	
Meprobamate	N05BC01	NE	
Meprobamate in association	N05CX01	NE	
Meprobamate, combinations	N05BC51	NE	
Meprotixol	R05DB22	NE	
Meptazinol	N02AX05	NE	
Mepyramine	D04AA02	0	<ul style="list-style-type: none"> • No special advice
Mepyramine	R06AC01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Mequinol	D11AX06	0	<ul style="list-style-type: none"> • No special advice
Mequitazine	R06AD07	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when

			taking this medicine.
Mercaptamine	A16AA04	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Mercuric amidochloride	D08AK01	NE	
Mercuric chloride	D08AK03	NE	
Mercuric iodide	D08AK30	NE	
Mercurochrome	D08AK04	0	<ul style="list-style-type: none"> No special advice
Mercury compounds	S01AX01	NE	
Mercury, metallic	D08AK05	NE	
Mersalyl	C03BC01	NE	
Mesalazine	A07EC02	0	<ul style="list-style-type: none"> No special advice
Mesna	R05CB05	NE	
Mesoridiazine	N05AC03	NE	
Mesulfen	D10AB05	NE	
Mesuximide	N03AD03	NE	
Metabutethamine	N01BA01	NE	
Metahexamide	A10BB10	NE	
Metamfetamine	N06BA03	NE	
Metamizole sodium (noramydopyrine)	N02BB02	NE	
Metamizole sodium, combinations excl. Psycholeptics	N02BB52	NE	
Metamizole sodium, combinations with. Psycholeptics	N02BB72	NE	
Metandienone	A14AA03 D11AE01	NE	
Metaraminol	C01CA09	NE	
Metenolone	A14AA04	0	<ul style="list-style-type: none"> No special advice
Metformin	A10BA02	0	<ul style="list-style-type: none"> No special advice

Metformin and pioglitazone	A10BD05	0	<ul style="list-style-type: none"> • No special advice
Metformin and rosiglitazone	A10BD03	0	<ul style="list-style-type: none"> • No special advice
Metformin and sitagliptin	A10BD07	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Metformin and sulfonamides	A10BD02	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Metformin and vildagliptin	A10BD08	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Methabarbital	N03AA30	NE	
Methadone - Oral administration: - Parenteral administration	N07BC02	II III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • Advise the patient to strictly follow the prescribed doses, the treatment and delivery procedures and to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioural changes and requires follow-up and counselling.

			<ul style="list-style-type: none"> • Driving with this treatment should require an approval by driving licence administration.
Methadone. Comb. Excl. Psycholectics	N02AC52	NE	
Methantheline	A03AB07	NE	
Methapyrilene	R06AC05	NE	
Methaqualone	N05CM01	NE	
Methaqualone, combinations	N05CX02	NE	
Methazolamide	S01EC05	NE	
Methdilazine	R06AD04	NE	
Methiosulfonium chloride	A02BX04	NE	
Methocarbamol	M03BA03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Methocarbamol, combinations excl. psycholeptics	M03BA53	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Methocarbamol, combinations with psycholeptics	M03BA73	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness)

			<ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Methohexital	N01AF01	NE	
Methoserpidine	C02AA06	NE	
Methoserpidine and diuretics	C02LA04	NE	
Methoxamine	C01CA10	NE	
Methoxsalen	D05AD02	NE	
Methoxsalen	D05BA02	0	<ul style="list-style-type: none"> • No special advice
Methoxy polyethylene glycol-epoetin beta	B03XA03	0	<ul style="list-style-type: none"> • No special advice
Methoxyflurane	N01AB03	NE	
Methoxyphenamine	R03CB02	NE	
Methyclothiazide	C03AA08	NE	
Methyclothiazide and potassium.	C03AB08	NE	
Methylatropine	A03BB02	NE	
Methylcellulose	A06AC06	0	<ul style="list-style-type: none"> • No special advice
Methyldigoxin	C01AA08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Methyldopa (levorotatory)	C02AB01	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.

Methyldopa (levorotatory) and diuretics	C02LB01	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Methyldopa (racemic)	C02AB02	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Methylhomatropine and psycholeptics	A03CB04	NE	
Methylnaltrexone Bromide	A06AH01	0	<ul style="list-style-type: none"> • No special advice
Methylpentynol	N05CM15	NE	
Methylpentynol, combinations	N05CX03	NE	
Methylphenidate	N06BA04	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Methylphenobarbital	N03AA01	NE	
Methylprednisolone	D07AA01	NE	
Methylprednisolone	D10AA02	0	
Methylprednisolone aceponate	D07AC14	0	<ul style="list-style-type: none"> • No special advice
Methylprednisolone and	D07CA02	NE	

antibiotics			
Methylprednisolone and antiinfectives	S01CA08	NE	
Methylpropylpropanediol dinitrate	C01DA04	NE	
Methylpropylpropanediol dinitrate, combinations	C01DA54	NE	
Methylprylon	N05CE02	NE	
Methylrosaniline	D01AE02	0	• No special advice
Methylscopolamine	A03BB03 S01AF03	NE	
Methylscopolamine and psycholeptics (with Chlordiazepoxide)	A03CB01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, visual accommodation disturbances, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights). • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Methysergide	N02CA04	NE	
Meticrane	C03BA09	NE	
Metipranolol	S01ED04	NE	
Metipranolol and thiazides, combinations	C07BA68	NE	
Metipranolol, combinations	S01ED54	NE	
Metirosine	C02KB01	NE	
Metixene	N04AA03	NE	
Metizoline	R01AA10	NE	
Metoclopramide - Oral administration	A03FA01	I	<p>Oral administration</p> <ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. possible visual accommodation disturbances), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when

- Parenteral administration		II	taking this medication. Parenteral administration <ul style="list-style-type: none"> • Inform the patient that this medication causes visual accommodation disturbances so you should not drive or operate machinery after parenteral administration until vision has normalised. • Advise the patient that he should wait until his sight returns to normal before driving or using any tools or machines.
Metolazone	C03BA08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Metolazone and potassium-sparing agents (spironolactone)	C03EA12	NE	
Metopimazine	A04AD05	NE	
Metoprolol	C07AB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Metoprolol - chlortalidone	C07BB02	NE	
Metoprolol - felodipin	C07FB02	NE	
Metoprolol and other antihypertensives	C07FB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Metoprolol and other diuretics	C07CB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.

Metoprolol and thiazides	C07BB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Metoprolol and thiazides, combinations	C07BB52	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Metoprolol, combinations	C07AB52	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Metronidazole	A01AB17 D06BX01	0	<ul style="list-style-type: none"> • No special advice
Mexiletine	C01BB02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Mianserin	N06AX03	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Miconazole	A01AB09 A07AC01 D01AC02	0	<ul style="list-style-type: none"> • No special advice

Miconazole	S02AA13	NE	
Miconazole, combinations	D01AC52	0	• No special advice
Micronomicin	S01AA22	NE	
Midazolam	N05CD08	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 24 hours. Advise your patient not to drive then.
Midodrine	C01CA17	NE	
Miglitol	A10BF02	0	• No special advice
Miglustat	A16AX06	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness and fatigue) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Milnacipran	N06AX17	NE	
Milrinone	C01CE02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Minaprine	N06AX07	NE	
Mineral salts in combination	A06AD10	NE	
Minocycline	A01AB23	0	• No special advice
Minoxidil	C02DC01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Minoxidil	D11AX01	0	• No special advice

Mirtazapine	N06AX11	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Misoprostol	A02BB01	0	<ul style="list-style-type: none"> • No special advice
Mitiglinide	A10BX08	NE	
Mivacurium chloride	M03AC10	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Mizolastine	R06AX25	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Moclobemide	N06AG02	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Modafinil	NO6BA07	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.).

			<ul style="list-style-type: none"> • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Moexipril	C09AA13	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Moexipril and diuretics	C09BA13	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Mofebutazone	M01AA02 M02AA02	NE	
Molindone	N05AE02	NE	
Molsidomine	C01DX12	NE	
Mometasone	D07AC13 D07XC03 R01AD09 R03BA07	0	<ul style="list-style-type: none"> • No special advice • No special advice • No special advice
Monobenzone	D11AX13	NE	
Monoethanolamine oleate	C05BB01	0	<ul style="list-style-type: none"> • No special advice
Monoxerutin	C05CA02	0	<ul style="list-style-type: none"> • No special advice
Montelukast	R03DC03	0	<ul style="list-style-type: none"> • No special advice
Moperone	N05AD04	NE	
Moracizine	C01BG01	NE	
Morclofone	R05DB25	NE	

Morniflumate	M01AX22	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Morphine - Oral administration - Parenteral administration	N02AA01	III/II* III *) prolonged release formulation; when a steady state of dosage has been reached	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Morphine and antispasmodics	N02AG01	NE	
Morphine combinations	N02AA51	NE	
Morphine, combinations.	A07DA52	II	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects (dizziness, drowsiness and somnolence) Patients receiving it should not drive or operate machinery unless it has been shown that their physical and mental capacity remains unaffected. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Morpholine salicylate	N02BA08	NE	
Mosapramine	N05AX10	NE	
Motretinide	D10AD05	NE	
Moxaverine	A03AD30	NE	
Moxifloxacin	S01AX22	0	<ul style="list-style-type: none"> • No special advice
Moxisylyte	C04AX10	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Moxonidine	C02AC05	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Moxonidine and diuretics	C02LC05	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Multienzymes (lipase, protease etc.)	A09AA02	0	<ul style="list-style-type: none"> • No special advice
Multienzymes and acid preparations	A09AC02	NE	
Multivitamins and calcium	A11AA02	0	<ul style="list-style-type: none"> • No special advice
Multivitamins and iron	A11AA01	0	<ul style="list-style-type: none"> • No special advice
Multivitamins and other minerals, incl. combinations	A11AA03	0	<ul style="list-style-type: none"> • No special advice
Multivitamins and trace elements	A11AA04	0	<ul style="list-style-type: none"> • No special advice
Mupirocin	D06AX09 R01AX06	0	<ul style="list-style-type: none"> • No special advice • No special advice
Muzolimine	C03CD01	NE	
Myristyl-benzalkonium	R02AA10	NE	
N	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT

Nabilone	A04AD11	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (drowsiness, vertigo/dizziness, euphoria (high), ataxia, visual disturbance, concentration difficulties, sleep disturbance, dysphoria). • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment, because the effects of this medicine may persist for a variable and unpredictable period of time following its oral administration and also to be careful in other situations (e.g. using machinery and working at heights). • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Nabumetone	M01AX01	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Nadolol	C07AA12	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nadolol and thiazides	C07BA12	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nadroparin	B01AB06	0	<ul style="list-style-type: none"> • No special advice
Naftidrofuryl	C04AX21	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Naftifine	D01AE22	0	<ul style="list-style-type: none"> • No special advice

Nalbuphine	N02AF02	NE	
Naltrexone	N07BB04	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • Advise the patient to strictly follow the prescribed doses and to avoid any alcohol or other psychoactive substances during the treatment. • Alcohol cessation can also cause behavioural changes and requires follow-up and counselling. • Driving with this treatment should require an approval by driving licence administration.
Nandrolone	A14AB01	0	<ul style="list-style-type: none"> • No special advice
Nandrolone	S01XA11	NE	
Naphazoline	R01AA08	0	<ul style="list-style-type: none"> • No special advice
Naphazoline	R01AB02	NE	
Naphazoline	S01GA01	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased redness, blurring, punctate keratitis, lacrimation with an increase in intraocular pressure and systemic effects due to absorption (hypertension, cardiac irregularities and hyperglycaemia). Some patients may experience drowsiness. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Naphazoline, combinations	S01GA51	Depending on the medicine in combination	<ul style="list-style-type: none"> • Depending on the medicine in combination
Naproxen	M02AA12	NE	
Naproxen	M01AE02 N02BG	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Naratriptan	N02CC02	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions.

			<ul style="list-style-type: none"> • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Narcobarbital	N01AG01	NE	
Natamycin	A01AB10 A07AA03 D01AA02 S01AA10	NE	
Nateglinide	A10BX03	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Natural phospholipids	R07AA02	NE	
Nebivolol	C07AB12	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nedocromil	R01AC07 R03BC03	0	<ul style="list-style-type: none"> • No special advice
Nedocromil	S01GX04	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.

Nefazodone	N06AX06	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Nefopam	N02BG06	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme.. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Neltenexine	R05CB14	NE	
Neomycin	A01AB08 A07AA01 D06AX04	0	<ul style="list-style-type: none"> • No special advice
Neomycin	B05CA09 R02AB01 S02AA07 S03AA01	NE	
Neomycin - Drops - Ointment	S01AA03	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Neomycin, combinations	A07AA51	0	<ul style="list-style-type: none"> • No special advice
Neostigmine - Oral administration	N07AA01	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment.

- Parenteral administration		III	• The treatment can impair patient's vision especially by night.
Neostigmine	S01EB06	NE	
Neostigmine, combinations	N07AA51	NE	
Nepafenac	S01BC10	NE	
Nepinalone	R05DB26	NE	
Nesiritide	C01DX19	NE	
Netilmicin	S01AA23	NE	
Nialamide	N06AF02	NE	
Niaprazine	N05CM16	NE	
Nicardipine	C08CA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nicergoline	C04AE02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Niceritrol	C10AD01	NE	
Nicofetamide	A03AC04	NE	
Nicofuranose	C10AD03	NE	
Nicomorphine	N02AA04	NE	
Nicorandil	C01DX16	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nicotinamide	A11HA01	0	• No special advice
Nicotine	N07BA01	0	<ul style="list-style-type: none"> • The treatment has to be used according to the recommended dose to avoid side effect on driving. • Smoking cessation can also cause behavioural changes.
Nicotinic acid	C04AC01	0	• No special advice

	C10AD02		
Nicotinic acid, combinations	C10AD52	0	• No special advice
Nicotinyl alcohol (pyridylcarbinol)	C04AC02 C10AD05	NE	
Nicotinyl methylamide	A05AB01	NE	
Nifedipine	C08CA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nifedipine, combinations	C08CA55	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nifenazone	M02AA24 N02BB05	NE	
Nifenazone		NE	
Niflumic acid	M01AX02	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Niflumic acid (topic use)	M02AA17	0	• No special advice
Nifuroxazide	A07AX03	NE	
Nifurzide	A07AX04	NE	
Nikethamide	R07AB02	NE	
Nikethamide, combinations	R07AB52	NE	
Nilvadipine	C08CA10	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when

			taking this medication.
Nimesulide	M01AX17	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Nimodipine	C08CA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Niperotidine	A02BA05	NE	
Nisoldipine	C08CA07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nitisinone	A16AX04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. conjunctivitis, corneal opacity, keratitis, photophobia, eye pain, etc.) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Nitrazepam	N05CD02	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time(occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Nitrendipine	C08CA08	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nitric oxide	R07AX01	0	<ul style="list-style-type: none"> • No special advice
Nitrofurantoin	D08AF01 D09AA03	0	<ul style="list-style-type: none"> • No special advice
Nitrofurantoin	B05CA03 S01AX04 S02AA02	NE	
Nitroprusside	C02DD01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Nitrous acid combinations	N01AX63	NE	
Nitrous oxide	N01AX13	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Nizatidine	A02BA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Nizofenone	N06BX10	NE	
Nomifensine	N06AX04	NE	
Nonacog alfa	B02BD09	0	<ul style="list-style-type: none"> • No special advice
Nordazepam	N05BA16	NE	

Norepinephrine	C01CA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Norethandrolone	A14AA09	NE	
Norfenefrine	C01CA05	NE	
Norfloxacin	S01AX12	0	<ul style="list-style-type: none"> • No special advice
Normethadone	R05DA06	NE	
Nortriptyline	N06AA10	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Noscapine	R05DA07	0	<ul style="list-style-type: none"> • No special advice
Noxytiolin	B05CA07	NE	
Nystatin	A07AA02 D01AA01	0	<ul style="list-style-type: none"> • No special advice • No special advice
O	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Octinoxate	D02BA02	0	<ul style="list-style-type: none"> • No special advice
Octopamine	C01CA18	NE	
Ofloxacin	S01AX11	0	<ul style="list-style-type: none"> • No special advice
Ofloxacin	S02AA16	NE	
Oil	A06AG06	0	<ul style="list-style-type: none"> • No special advice
Olafur	A01AA03	NE	
Olanzapine	N05AH03		Oral administration:

			until they have cleared before driving or using machinery.
Olopatadine	R01AC08	NE	
Olsalazine	A07EC03	0	• No special advice
Omalizumab	R03DX05	0	• No special advice
Omega-3-triglycerides	C10AX06	NE	
Omeprazole	A02BC01	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Omeprazole, amoxicillin and clarithromycin	A02BD05	NE	
Omeprazole, amoxicillin and metronidazole	A02BD01	NE	
Omoconazole	D01AC13	NE	
Ondansetron	A04AA01	0	• No special advice
Opi Pramol	N06AA05	NE	
Opium	A07DA02	II	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects (dizziness, drowsiness and somnolence) Patients receiving it should not drive or operate machinery unless it has been shown that their physical and mental capacity remains unaffected. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Opium	N02AA02	NE	
Opium alkaloids with morphine	R05DA05	NE	
Opium derivatives and expectorants	R05FA02	II or higher depending on the medicine in combination	• II or higher depending on the medicine in combination
Opium derivatives and mucolytics	R05FA01	NE	
Oral rehydration salt formulations	A07CA	0	• No special advice
Orciprenaline	R03AB03	NE	

Orciprenaline	R03CB03	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (anxiety, restlessness, insomnia, tremor) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Orciprenaline, combinations	R03CB53	NE	
Ordinary salt combinations	A02AD01	0	<ul style="list-style-type: none"> • No special advice
Ordinary salt combinations and antifatulents	A02AF02	0	<ul style="list-style-type: none"> • No special advice
Organic nitrates in combination	C01DA20	NE	
Organic nitrates in combination with psycholeptics	C01DA70	NE	
Organo-heparinoid	C05BA01	0	<ul style="list-style-type: none"> • No special advice
Orgotein	M01AX14	NE	
Orlistat	A08AB01	0	<ul style="list-style-type: none"> • No special advice
Ornithine oxoglurate	A05BA06	NE	
Orphenadrine	N04AB02	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Orphenadrine (citrate)	M03BC01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when

			<p>taking this medicine.</p> <ul style="list-style-type: none"> • One time (occasional) use: inform your patient that his/her response is reduced. Advice your patient not to drive then.
Orphenadrine, combinations	M03BC51	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advice your patient not to drive then.
Other emollients and protectives	D02AX	0	<ul style="list-style-type: none"> • No special advice
Other plasma protein fractions	B05AA02	NE	
Other preparations, combinations	C05AX03	0	<ul style="list-style-type: none"> • No special advice
Others (Medicated shampoos)	D11AC30	NE	
Otilonium bromide	A03AB06	0	<ul style="list-style-type: none"> • No special advice
Otilonium bromide and psycholeptics	A03CA04	NE	
Oxabolone cipationate	A14AB03	NE	
Oxaceprol	D11AX09 M01AX24	NE	
Oxaflozane	N06AX10	NE	
Oxametacin	M01AB13	NE	
Oxandrolone	A14AA08	NE	
Oxaprotilin	N06AA Not yet determined	NE	
Oxaprozin	M01AE12	NE	
Oxatomide	R06AE06	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness,

			<p>sleepiness, blurred vision and reduced alertness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Oxazepam	N05BA04	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Oxcarbazepine	N03AF02	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Oxedrine	C01CA08 S01GA06	NE	
Oxedrine, combinations	S01GA56	NE	
Oxeladin	R05DB09	NE	
Oxetacaine	C05AD06	0	• No special advice
Oxetorone	N02CX06	NE	
Oxiconazole	D01AC11	0	• No special advice
Oxidized cellulose	B02BC02	NE	
Oxiracetam	N06BX07	NE	
Oxitriptan	N06AX01	NE	
Oxitropium bromide	R03BB02	NE	

Oxolamine	R05DB07	NE	
Oxomemazine	R06AD08	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Oxovinca	(C04AX) Not yet determined	NE	
Oxprenolol	C07AA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Oxprenolol - chlortalidone	(C07BA) Not yet determined	NE	
Oxprenolol and other diuretics	C07CA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Oxprenolol and thiazides	C07BA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Oxybuprocaine	D04AB03	NE	
Oxybuprocaine	S01HA02	I	<ul style="list-style-type: none"> • Inform the patient that his/her eyesight may become blurred. • Advise him/her not to drive or operate machinery during the first 24 hours following the use of a local anaesthetic.

Oxycinchophen	M01CA03	NE	
Oxycodone	N02AA05	III/II* *) prolonged release formulation; when a steady state of dosage has been reached	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Oxyfedrine	C01DX03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Oxyfedrine, combinations	C01DX53	NE	
Oxymetazoline	R01AA05	0	<ul style="list-style-type: none"> • No special advice
Oxymetazoline	R01AB07	NE	
Oxymetazoline	S01GA04	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased redness, blurring, punctate keratitis, lacrimation with an increase in intraocular pressure and systemic effects due to absorption (hypertension, cardiac irregularities and hyperglycaemia). Some patients may experience drowsiness. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Oxymetholone	A14AA05	NE	
Oxymorphone	(N02AA) Not yet determined	NE	
Oxypertine	N05AE01	NE	
Oxyphenbutazone	M01AA03	NE	

	M02AA04 S01BC02		
Oxyphencyclimine	A03AA01	NE	
Oxyphencyclimine and psycholeptics	A03CA03	NE	
Oxyphenisatine	A06AB01	NE	
Oxyphenonium	A03AB03	NE	
Oxyquinoline	A01AB07	0	• No special advice
Oxyquinoline	D08AH03	NE	
Oxyquinoline	R02AA14	NE	
Oxytetracycline	D06AA03		• No special advice
Oxytetracycline - Drops - Ointment	S01AA04	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
P	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Paliperidone	N05AX13	NE	
Palonosetron	A04AA05	0	• No special advice
Pamidronic acid	M05BA03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Pancuronium	M03AC01	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after

			anaesthesia
Pantethine	A11HA32	NE	
Pantoprazole	A02BC02	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Pantoprazole, amoxicillin and clarithromycin	A02BD04	NE	
Papaveretum	N02AA10	NE	
Papaverine	A03AD01	NE	
Paracetamol	N02BE01	0	<ul style="list-style-type: none"> No special advice.
Paracetamol, combinations excl psycholeptics	N02BE51	NE	
Paracetamol, combinations with Psycholeptics	N02BE71	NE	
Paraldehyde	N05CC05	NE	
Paramethadione	N03AC01	NE	
Paraoxon	S01EB10	NE	
Parecoxib	M01AH04 N02BG	I	<ul style="list-style-type: none"> Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Pargyline	C02KC01	NE	
Pargyline and diuretics	C02LL01	NE	
Parnaparin	B01AB07	NE	
Paromomycin	A07AA06	0	<ul style="list-style-type: none"> No special advice
Paroxetine	N06AB05	I	<ul style="list-style-type: none"> Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. Advise your patient not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Passiflore aubepine	C01EB Not yet determined	NE	
Passiflore-extract	N05CM20	NE	
Pecilocin	D01AA04	NE	
Pectin	A07BC01	0	<ul style="list-style-type: none"> • No special advice
Pegaptanib	S01LA03	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient visual disturbances such as abnormal vision, vision decrease, or visual field defects that may interfere with their ability to drive or use machines. Patients should not drive or use machines as long as these symptoms persist. • Advise the patients not to drive or operate hazardous machinery until your vision improves.
Pegloticase	M04AX02	NE	
Pemoline	N06BA05	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Penbutolol	C07AA23	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Penbutolol and other diuretics	C07CA23	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.

Penciclovir	D06BB06	0	• No special advice
Penfluridol	N05AG03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Penicillamine	M01CC01	0	• No special advice
Pentaerithryl	A06AD14	NE	
Pentaerithryl tetranitrate	C01DA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Pentaerithryl tetranitrate, combinations	C01DA55	NE	
Pentazocine	N02AD01	NE	
Pentetrazol	R07AB03	NE	
Pentetrazol, combinations	R07AB53	NE	
Penthienate	A03AB04	NE	
Pentifylline	C04AD01	NE	
Pentobarbital	N05CA01	NE	
Pentosan polysulfate sodium	C05BA04	0	• No special advice
Pentoxifylline	C04AD03	0	• No special advice
Pentoxyverine	R05DB05	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (drowsiness, sleepiness) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Pepsin	A09AA03	0	• No special advice

Pepsin and acid preparations	A09AC01	NE	
Perazine	N05AB10	NE	
Pergolide	N04BC02	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks” • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Perhexiline	C08EX02	NE	
Periciazine	N05AC01	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Perindopril	C09AA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Perindopril and amlodipine	C09BB04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Perindopril and diuretics	C09BA04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Perphenazine	N05AB03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the

			<p>medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Peruvoside	C01AX02	NE	
Pethidine	N02AB02	III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Pethidine and antispasmodics	N02AG03	NE	
Pethidine, combinations excl. Psycholeptics	N02AB52	NE	
Pethidine, combinations with. Psycholeptics	N02AB72	NE	
Phedrine	R01AA03	0	<ul style="list-style-type: none"> • No special advice
Phenacemide	N03AX07	NE	
Phenacetin	N02BE03	NE	
Phenacetin, combinations excl. Psycholeptics	N02BE53	NE	
Phenacetin, combinations with Psycholeptics	N02BE73	NE	
Phenazone	N02BB01 S02DA03	NE	
Phenazone, combinations excl. Psycholeptics	N02BB51	NE	
Phenazone, combinations	N02BB71	NE	

with. Psycholeptics			
Phenelzine	N06AF03	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Pheneturide	N03AX13	NE	
Phenformin	A10BA01	NE	
Phenformin and sulfonamides	A10BD01	NE	
Phenglutarimide	N04AA09	NE	
Phenindamine	R06AX04	NE	
Phenindione	B01AA02	NE	
Pheniramine	R06AB05	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, restlessness, sedation) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Phenobarbital	N03AA02	III	<p>Advise the patient not to drive.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Phenobarbital - calcium gluconate and bromate	C01EB Not yet	NE	

			<p>sleepiness, blurred/double vision and reduced alertness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Phenprobamate, combinations excl. psycholeptics	M03BA51	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Phenprobamate, combinations with psycholeptics	M03BA71	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Phenprocoumon	B01AA04	NE	
Phensuximide	N03AD02	NE	
Phentermine	A08AA01	NE	
Phentolamine	C04AB01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Phenylbutazone	M01AA01 M02AA01	NE	
Phenylbutazone and corticosteroids	M01BA01	NE	
Phenylephrine	R01AA04	0	<ul style="list-style-type: none"> No special advice
Phenylephrine	R01BA03	0	<ul style="list-style-type: none"> No special advice
Phenylephrine	C01CA06	NE	
Phenylephrine (<<< 10%, 0.125%)	S01GA05	I	<ul style="list-style-type: none"> Inform the patient that this ocular medication may cause side effects including local irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased redness, blurring, punctate keratitis, lacrimation with an increase in intraocular pressure and systemic effects due to absorption (hypertension, cardiac irregularities and hyperglycaemia). Some patients may experience drowsiness. Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Phenylephrine (≥ 10%)	S01FB01	III	<ul style="list-style-type: none"> Inform the patient that this ocular medication may cause eye pain and stinging on instillation, transient blurring of vision or that he/she may suffer from photophobia, conjunctival sensitization and allergy as well as systemic effects: palpitations, tachycardia, extrasystoles, cardiac arrhythmias, hypertension and serious cardiovascular reactions including coronary artery spasm, ventricular arrhythmias and myocardial infarctions and that this may impair their ability to drive under certain circumstances. Advise the patients not to drive or operate hazardous machinery until vision is clear or it has been shown that their physical and mental capacity remains unaffected.
Phenylephrine, combinations	R01BA53, S01GA55	Depending on the medicine in combination	<ul style="list-style-type: none"> Depending on the medicine in combination
Phenylephrine, sympathomimetics, combinations excl. corticosteroids	R01AB01	Depending on the medicine in combination	
Phenylephrine+tetracaine	S01FBP1	III	<ul style="list-style-type: none"> Inform the patient that this ocular medication may cause eye pain and stinging on

			<p>instillation, transient blurring of vision or that he/she may suffer from photophobia, conjunctival sensitization and allergy as well as systemic effects: palpitations, tachycardia, extrasystoles, cardiac arrhythmias, hypertension and serious cardiovascular reactions including coronary artery spasm, ventricular arrhythmias and myocardial infarctions and that this may impair their ability to drive under certain circumstances.</p> <ul style="list-style-type: none"> • Advise the patients not to drive or operate hazardous machinery until vision is clear or it has been shown that their physical and mental capacity remains unaffected.
Phenylmercuric borate	D08AK02	NE	
Phenylmercuric nitrate	D09AA04	NE	
Phenylpropanolamine	R01BA01	0	<ul style="list-style-type: none"> • No special advice
Phenylpropanolamine, Combinations	R01BA51	NE	
Phenytoin - Oral administration - Parenteral administration	N03AB02	III III	<p>Advise the patient not to drive.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication. <p>Trigeminal neuralgia</p> <ul style="list-style-type: none"> • Advise the patient not to drive.
Phenytoin, combinations	N03AB052	III	<p>Advise the patient not to drive.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication
Phloroglucinol	A03AX12	NE	
Pholcodine	R05DA08	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, excitation, confusion)

			<ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Phthalylsulfathiazole	A07AB02	NE	
Physostigmine	S01EB05	NE	
Phytomenadione	B02BA01	0	<ul style="list-style-type: none"> • No special advice
Picloxidine	S01AX16	NE	
Picodralazine and diuretics	C02LG03	NE	
Picodralazine and diuretics, combinations with psycholeptics.	C02LG73	NE	
Picotamide	B01AC03	NE	
Pilocarpine	N07AX01	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • The treatment can impair patient's vision especially by night and may require an ophthalmological advice.
Pilocarpine	S01EB01	II	<ul style="list-style-type: none"> • Inform the patient that this ocular medication causes miosis which usually results in difficulties for his/her sight to adapt to the dark. • Advise the patients to exercise caution in night driving and other hazardous occupations in conditions of poor illumination.
Pilocarpine, combinations	S01EB51	NE	
Pimecrolimus (topical use)	D11AH02	0	<ul style="list-style-type: none"> • No special advice
Pimethixene	R06AX23	II	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (drowsiness, somnolence) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Pimozide	N05AG02	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness,

			<p>sleepiness, blurred/double vision and reduced alertness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Pinacidil	C02DG01	NE	
Pinacidil and diuretics	C02LX01	NE	
Pinaverium	A03AX04	0	<ul style="list-style-type: none"> • No special advice
Pinazepam	N05BA14	NE	
Pindolol	C07AA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Pindolol and other diuretics	C07CA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Pioglitazone	A10BG03	0	<ul style="list-style-type: none"> • No special advice
Pioglitazone and alogliptin	A10BD09	NE	
Pipamperone	N05AD05	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Pipazetate	R05DB11	NE	
Pipecuronium bromide	M03AC06	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia

Pipenzolate	A03AB14	NE	
Piperidione	R05DB23	NE	
Piperidolate	A03AA30	NE	
Pipotiazine palmitate: injection depot i.m.	N05AC04	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Pipradrol	N06BX15	NE	
Piprozolin	A05AX01	NE	
Piracetam	N06BX03	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Pirbuterol	R03AC08 R03CC07	NE	
Pirenzepine	A02BX03	NE	
Piretanide	C03CA03	0	<ul style="list-style-type: none"> • No special advice
Piribedil	N04AX13 C04AX13	II	<ul style="list-style-type: none"> • Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Piribedil	N04BC08	NE	
Pirisunadol	N06BX08	NE	

Piritramide	N02AC03	NE	
Pirlindole	N06AF Not yet determined	NE	
Piroxicam	M01AC01	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Piroxicam	S01BC06	NE	
Piroxicam (topical use)	M02AA07	0	
Pirprofen	M01AE08	NE	
Pitavastatin	C10AA08	NE	
Pitofenone and analgesics	A03DA02	NE	
Pivagabine	N06AX15	NE	
Pizotifen	N02CX01	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Podophyllotoxin	D06BB04	0	<ul style="list-style-type: none"> • No special advice
Poldine	A03AB11	NE	
Policosanol	C10AX08	NE	
Policresulen	D08AE02	NE	
Polidocanol	C05BB02	0	<ul style="list-style-type: none"> • No special advice
Polihexanide	D08AC05	NE	
Polycarbophil calcium	A06AC08	NE	

Polymyxin	S02AA11	NE	
Polymyxin B	A07AA05 S01AA18 S03AA03	NE	
Polynoxylin	A01AB05 D01AE05	NE	
Polythiazide	C03AA05	NE	
Polythiazide and potassium	C03AB05	NE	
Potassium acetate	B05XA17	0	• No special advice
Potassium canrenoate	C03DA02	0	• No special advice
Potassium chloride	A12BA01 B05XA01	0	• No special advice
Potassium chloride, Combinations	A12BA51	Depending on the medicine in combination	• Depending on the medicine in combination
Potassium citrate	A12BA02	0	• No special advice
Potassium clorazepate - Oral administration	N05BA05	II	Oral administration • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
- Parenteral administration		III	• Parenteral administration • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to

			<p>be careful in other situations (e.g. using machinery and working at heights)</p> <ul style="list-style-type: none"> • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Potassium gluconate	A12BA05	0	• No special advice
Potassium hydrogencarbonate	A12BA04	0	• No special advice
Potassium hydrogentartrate	A12BA03	0	• No special advice
Potassium iodide	R05CA02 S01XA04	NE	
Potassium lactate	B05XA15	0	• No special advice
Potassium permanganate	D08AX06	NE	
Potassium phosphate, incl. comb. with other potassium salts	B05XA06	0	• No special advice
Potassium salicylate	N02BA12	NE	
Povidone-iodine	D08AG02 D09AA09 D11AC06 R02AA15	0	• No special advice
Povidone-iodine	S01AX18	NE	
Practolol	C07AB01	NE	
Prajmaline	C01BA08	NE	
Pramipexole	N04BC05	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks" • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).
Pramlintide	A10BX05	NE	
Pramocaine	C05AD07	0	• No special advice

	D04AB07		
Pranlukast	R03DC02	NE	
Pranoprofen	S01BC09	0	• No special advice
Prasterone	A14AA07	NE	
Prasugrel	B01AC22	0	• No special advice
Pravastatin	C10AA03	0	• No special advice
Pravastatin and acetylsalicylic acid	C10BX02	NE	
Pravastatin and fenofibrate	C10BA03	0	• No special advice
Prazepam	N05BA11	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 3 days to one week. Advise your patient not to drive then.
Prazosin	C02CA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Prazosin and diuretics	C02LE01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Prednicarbate	D07AC18	0	• No special advice
Prednisolone	A07EA01 C05AA04 D07AA03	0	• No special advice

	D07XA02 S01BA04		
Prednisolone	R01AD02 S02BA03 S03BA02	NE	
Prednisolone (Corticosteroids/antiinfectives/ mydriatics in combination)	S01CB02	Depending on the mydriatic in combination	<ul style="list-style-type: none"> • Depending on the mydriatic in combination
Prednisolone and antibiotics	D07CA03	NE	
Prednisolone and antiinfectives - Drops - Ointment	S01CA02	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Prednisolone and antiinfectives	S02CA01	NE	
Prednisolone and antiinfectives	S03CA02	0	<ul style="list-style-type: none"> • No special advice
Prednisolone and antiseptics	D07BA01	NE	
Prednisolone and mydriatics	S01BB02	Depending on the mydriatic in combination	<ul style="list-style-type: none"> • Depending on the mydriatic in combination
Prednisolone, Combinations	A01AC54	0	<ul style="list-style-type: none"> • No special advice
Prednisolone, combinations	R01AD52	NE	
Prednisone	A07EA03	0	<ul style="list-style-type: none"> • No special advice
Pregabalin	N03AX16	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication. <p>Neuropathic pain; Generalised Anxiety Disorder</p>

			<ul style="list-style-type: none"> Advise the patient not to drive during the first days of treatment as well as after dose increases.
Prenalterol	C01CA13	NE	
Prenoxdiazine	R05DB18	NE	
Prenylamine	C01DX02	NE	
Prenylamine, combinations	C01DX52	NE	
Prethcamide	R07AB06	NE	
Pridinol	M03BX03	II	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Prifinium bromide	A03AB18	NE	
Prilocaine	N01BB04		<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p>0 <u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <p>I <ul style="list-style-type: none"> Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. </p> <p>II <u>Ocular administration:</u></p> <ul style="list-style-type: none"> Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p>III <u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p>

			<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Prilocaine combinations	N01BB54	<p>0</p> <p>I</p> <p>II</p> <p>III</p>	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Primidone	N03AA03	III	<p>Advise the patient not to drive.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.

			Essential tremor • Advise the patient not to drive
Probenecid	M04AB01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. somnolence, dizziness vertigo or ataxia), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Probucol	C10AX02	NE	
Procainamide	C01BA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Procaine	C05AD05	0	• No special advice
Procaine	S01HA05	NE	
Procaine (Anesthetic, local)(En la otra table no aparece: "Anesthetic, local")	N01BA02	0 I II III	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia.

			<ul style="list-style-type: none"> Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Procaine combinations	N01BA52	<p>0</p> <p>I</p> <p>II</p> <p>III</p>	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia. Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Procaterol	R03AC16 R03CC08	NE	
Prochlorperazine	N05BA04	NE	
Procyclidine	N04AA04	II	<ul style="list-style-type: none"> Advise the patient (and explain to caregivers) not to drive during the first days of treatment. Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks". Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).

Profenamine	N04AA05	NE	
Progabide	N03AG05	NE	
Proglumetacin	M01AB14	NE	
Proglumide	A02BX06	NE	
Prolintane	N06BX14	NE	
Promazine	N05AA03	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Promethazine	D04AA10	0	<ul style="list-style-type: none"> • No special advice
Promethazine	R06AD02	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred vision, tremor and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Promethazine, combinations	R06AD52	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Propacetamol	N02BE05	NE	
Propafenone	C01BC03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist • Advise your patient not to drink alcohol nor use any psychoactive substances when

			taking this medication.
Propamidine	D08AC03	NE	
Propanamidine	S01AX15	NE	
Propanidid	N01AX04	NE	
Propranol	D08AX03	NE	
Propranol, combinations	D08AX53	NE	
Propranthele	A03AB05	0	• No special advice
Propranthele and psycholeptics	A03CA34	NE	
Propatylnitrate	C01DA07	NE	
Propatylnitrate, combinations	C01DA57	NE	
Propiomazine	N05CM06	NE	
Propiphenazone, combinations with. Psycholeptics	N02BB74	NE	
Propofol	N01AX10	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Propranolol	C07AA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Propranolol and other antihypertensives	C07FA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Propranolol and thiazides	C07BA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Propyphenazone	N02BB04	NE	
Propyphenazone, combinations excl. Psycholeptics	N02BB54	NE	
Proquazone	M01AX13	NE	
Proscillaridin	C01AB01	NE	
Proscillaridin, combinations	C01AB51	NE	
Protein C	B01AD12	0	<ul style="list-style-type: none"> • No special advice
Protein hydrolysates	B05BA04	0	<ul style="list-style-type: none"> • No special advice
Prothipendyl	N05AX07	NE	
Protriptyline	N06AA11	NE	
Proxazole	A03AX07	NE	
Proxibarbitol	N05CA22	NE	
Proxymetacaine	S01HA04	NE	
Proxiphylline	R03DA03	NE	
Proxiphylline and adrenergics	R03DB03	NE	
Prucalopride	A03AE04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness and fatigue) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Pseudoephedrine	R01BA02	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (anxiety, restlessness, tremor, insomnia) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.

Pseudoephedrine, combinations + loratadine	R01BA52	I	+ loratadine • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (anxiety, restlessness, tremor, insomnia, dizziness, fatigue) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
+ triprolidine		III	+ triprolidine • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (anxiety, restlessness, tremor, insomnia, drowsiness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Pyridostigmine	N07AA02	II	• Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • The treatment can impair patient's vision especially by night.
Pyridoxal phosphate	A11HA06	0	• No special advice
Pyridoxine (vit B6)	A11HA02	0	• No special advice
Pyrithione zinc	D11AX12	0	
Pyrithydione	N05CE03	NE	
Pyritinol	N06BX02	NE	
Pyrrbutamine	R06AX08	NE	
Pyrrbutamine, combinations	R06AX58	NE	
Pyrrloinitrin	D01AA07	NE	
Q	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Quazepam	N05CD10	NE	
Quetiapine	N05AH04	II	Start of treatment:

			<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. <p>Continuation treatment:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Quinapril	C09AA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Quinapril and diuretics	C09BA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Quinbolone	A14AA06	NE	
Quinethazone	C03BA02	NE	
Quinethazone and potassium	C03BB02	NE	
Quinidine	C01BA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Quinidine, combinations excl.	C01BA51	NE	

psycholeptics			
Quinidine, combinations with psycholeptics	C01BA71	NE	
Quinine, combinations with psycholeptics	M09AA72	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. visual disturbances, vertigo), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Quinisocaine	D04AB05	NE	
R	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Rabeprazole	A02BC04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Racecadotril	A07XA04	0	<ul style="list-style-type: none"> • No special advice
Ramelteon	N05CH02	NE	
Ramipril	C09AA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ramipril and diuretics	C09BA05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ramipril and felodipine	C09BB05	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ranibizumab	S01LA04	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient visual

			<p>disturbances such as abnormal vision, vision decrease, or visual field defects that may interfere with their ability to drive or use machines. Patients should not drive or use machines as long as these symptoms persist.</p> <ul style="list-style-type: none"> • Advise the patients not to drive or operate hazardous machinery until your vision improves.
Ranitidine	A02BA02	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Ranitidine bismuth citrate	A02BA07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Ranolazine	C01EB18	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Rasagiline	N04BD02	I	<p>Monotherapy:</p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. <p>In adjunct therapy with levodopa:</p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Rauwolfia alkaloids, whole root	C02AA04	NE	
Rauwolfia alkaloids, whole root and diuretics	C02LA08	NE	

Reboxetine	N06AX18	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Regadenoson	C01EB21	NE	
Remifentanyl	N01AH06	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Remikiren	C09XA01	NE	
Remoxipride	N05AL04	NE	
Repaglinide	A10BX02	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Reposal	N05CA12	NE	
Reproterol	R03AC15 R03CC14	NE	
Reproterol and other drugs for	R03AK05	NE	

obstructive airway diseases			
Rescinnamine	C02AA01	NE	
Rescinnamine and diuretics	C02LA02	NE	
Rescinnamine and diuretics, combinations with other drugs	C02LA52	NE	
Reserpine	C02AA02	NE	
Reserpine and diuretics	C02LA01	NE	
Reserpine and diuretics, combinations with other drugs	C02LA51	NE	
Reserpine and diuretics, combinations with psycholeptics	C02LA71	NE	
Reserpine, combinations	C02AA52	NE	
Resorcinol	D10AX02 S01AX06	NE	
Retapamulin	D06AX13	0	• No special advice
Reteplase	B01AD07	0	• No special advice
Retinol	D10AD02 R01AX02 S01XA02	NE	
Retinol (vit A)	A11CA01	0	• No special advice
Reviparin	B01AB08	NE	
Riboflavin (vit B2)	A11HA04	0	• No special advice
Rifamycin	S01AA16	0	• Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Rifamycin	S02AA12	NE	
Rifaximin	A07AA11	0	• No special advice
Rifaximin	D06AX11	NE	
Rilanomer	D03AX09	NE	
Rilmenidine	C02AC06	II	• Inform your patient that the medication can cause side effects that impair driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.).

			<ul style="list-style-type: none"> • Advise your patient not to drive for the first few days of treatment and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise the patient not to drink alcohol nor use any psychoactive substance when taking this medicine.
Riluzole	N07XX02	I	<ul style="list-style-type: none"> • The treatment has to be used according to the recommended dose to avoid side effect on driving. • Driving ability might be evaluated depending of the severity of the disease.
Rimazolium	N02BG02	NE	
Rimexolone - Drops - Ointment	S01BA13	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Rimiterol	R03AC05	NE	
Rimonabant	A08AX01	NE	
Risedronic acid	M05BA07	0	<ul style="list-style-type: none"> • No special advice
Risedronic acid and calcium, sequential	M05BB02	NE	
Risedronic acid, calcium and colecalciferol, sequential	M05BB04	NE	
Risperidone - Oral administration - Parenteral administration: depot i.m.	N05AX08	II III	<p>Oral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. <p>Parenteral administration</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to

			<p>be careful in other situations (e.g. using machinery and working at heights)</p> <ul style="list-style-type: none"> • Advise the patient not to drink alcohol when taking this medicine.
Ritanserin	N06AX Not yet determined	NE	
Ritiometan	R01AX05	NE	
Rivaroxaban	B01AX06	0	<ul style="list-style-type: none"> • No special advice
Rivastigmine	N06DA03	II	<ul style="list-style-type: none"> • Inform your patient (and explain his/her caregiver) about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient (and explain his/her caregiver) not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient (and explain his/her caregiver) not to drive because his/her driving skills are still impaired for approximately 24 hours. • Driving with this treatment should require an approval by driving licence administration.
Rizatriptan	N02CC04	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Rociverine	A03AA06	NE	
Rocuronium bromide	M03AC09	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the

			<p>anaesthetic, and the immediate effects of surgery have passed</p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Rofecoxib	M01AH02	NE	
Roflumilast	R03DX07	0	<ul style="list-style-type: none"> • No special advice
Romiplostim (subcutaneous via)	B02BX04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, paraesthesia, etc.) and not to drive as long as side-effects persist.
Ronifibrate	C10AB07	NE	
Ropinirole	N04BC04	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks" • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).
Ropivacaine	N01BB09	<p>0</p> <p>I</p> <p>II</p> <p>III</p>	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed. <p><u>Ocular administration:</u></p> <ul style="list-style-type: none"> • Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics. <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers), in the event an early discharge is

			<p>envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia.</p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Rosa bengal sodium	S01JA02	NE	
Rosiglitazone	A10BG02	0	<ul style="list-style-type: none"> • No special advice
Rosuvastatin	C10AA07	0	<ul style="list-style-type: none"> • No special advice
Rotigotin	N04BC09	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks". • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).
Roxatidine	A02BA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, and not to drive as long as side-effects persist.
Rufinamide	N03AF03	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Rupatadine	R06AX28	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, somnolence) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.

Rutoside	C05CA01	0	• No special advice
Rutoside, combinations	C05CA51	0	• No special advice
S	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Saccharated iron oxide	B03AC02	0	• No special advice
Saccharomyces boulardii	A07FA02	0	• No special advice
Sacrosidase	A16AB06	NE	
Salbutamol	R03AC02 R03CC02	0 0	• No special advice • No special advice
Salbutamol and other drugs for obstructive airway diseases	R03AK04	NE	
Salicylamide	N02BA05	NE	
Salicylamide , combinations with psycholeptics	N02BA75	NE	
Salicylamide, combinations excl. Psycholeptics	N02BA55	NE	
Salicylic acid	D01AE12	0	• No special advice
Salicylic acid	S01BC08	NE	
Salicylic acid preparations	D02AF	0	
Salmeterol	R03AC12	0	• No special advice
Salmeterol and other drugs for obstructive airway diseases	R03AK06	NE	
Salsalate	N02BA06	NE	
Sapropterin	A16AX07	0	• No special advice
Saruplase	B01AD08	NE	
S-atenol	C07AB11	NE	
Saxagliptin	A10BH03	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Scopolamine - Oral and rectal administration	A04AD01	I	<p>Oral and rectal administration</p> <ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. possible visual accommodation disturbances), and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
- Parenteral administration		II	<p>Parenteral administration</p> <ul style="list-style-type: none"> • Inform the patient that this medication causes visual accommodation disturbances so you should not drive or operate machinery after parenteral administration until vision has normalised. • Advise the patient that should wait until until your sight returns to normal before driving or using any tools or machines.
Scopolamine	N05CM05 S01FA02	NE	
Scopolamine, combinations	A04AD51	NE	
Selegiline	N04BD01	I	<p>Monotherapy:</p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. <p>In adjunct therapy with levodopa:</p> <ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Selenium compounds	D11AC03	0	<ul style="list-style-type: none"> • No special advice
Selenium sulfide	D01AE13	NE	
Senega	R05CA06	0	<ul style="list-style-type: none"> • No special advice

Senna glycosides	A06AB06	0	• No special advice
Senna glycosides, combinations	A06AB56	0	• No special advice
Seratrodast	R03DX06	NE	
Serobarbital	N05CA06	NE	
Sertaconazole	D01AC14	0	• No special advice
Sertindole	N05AE03	NE	
Sertraline	N06AB06	I	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities. • Advise your patient not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication.
Sevoflurane	N01AB08	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Sibutramine	A08AA10	NE	
Silicone products	D02AA	0	• No special advice
Silicones	A03AX13	0	• No special advice
Silver	D08AL30	NE	
Silver compounds	S01AX02	NE	
Silver nitrate	D08AL01	0	
Silver sulfadiazine	D06BA01	0	• No special advice

Silver sulfadiazine, combinations	D06BA51	0	• No special advice
Silymarin	A05BA03	0	• No special advice
Simfibrate	C10AB06	NE	
Simvastatin	C10AA01	0	• No special advice
Simvastatin and acetylsalicylic acid	C10BX01	NE	
Simvastatin and ezetimibe	C10BA02	0	• No special advice
Sitagliptin	A10BH01	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Sitaxentan	C02KX03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Sobrerol	R05CB07	NE	
Sodium acetate	B05XA08	0	• No special advice
Sodium apolate	C05BA02	0	• No special advice
Sodium aurothiomalate	M01CB01	0	
Sodium aurothiosulfate	M01CB02	NE	
Sodium bicarbonate	B05CB04 B05XA02	0	<ul style="list-style-type: none"> • No special advice • No special advice
Sodium borate	S01AX07	NE	
Sodium chloride	A12CA01 B05CB01 B05XA03	0	<ul style="list-style-type: none"> • No special advice • No special advice • No special advice
Sodium chloride, hypertonic	S01XA03	0	• No special advice

Sodium citrate	B05CB02	0	• No special advice
Sodium edetate	S01XA05	0	• No special advice
Sodium ferredetate	B03AB03	0	• No special advice
Sodium fluoride	A01AA01 A12CD01	0	• No special advice • No special advice
Sodium fluoride, combinations	A01AA51	NE	NE
Sodium glycerophosphate	B05XA14	0	• No special advice
Sodium hypochlorite	D08AX07	NE	
sodium Monofluorophosphate	A01AA02	NE	
Sodium monofluorophosphate	A12CD02	0	• No special advice
Sodium perborate	A01AB19	0	• No special advice
Sodium phenylbutyrate	A16AX03	I	• No special advice
Sodium phosphate	A06AG01 B05XA09	0	• No special advice
Sodium phosphate	A06AD17	NE	
Sodium picosulfate	A06AB08	0	• No special advice
Sodium picosulfate, combinations	A06AB58	0	• No special advice
Sodium propionate	S01AX10	NE	
Sodium salicylate	N02BA04	NE	
Sodium selenate	A12CE01	0	• No special advice
Sodium selenite	A12CE02	0	• No special advice
Sodium sulfate	A12CA02 A06AD13	0	• No special advice
Sodium tartrate	A06AD21	NE	
Sodium tetradecyl sulfate	C05BB04	0	• No special advice
Soft paraffin and fat products	D02AC	0	• No special advice
Sorbitol	B05CX02	0	• No special advice
Sorbitol	A06AD18 A06AG07	NE	
Sotalol	C07AA07	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Sotalol and thiazides	C07BA07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Sotalol, combination	C07AA57	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Spaglumic acid	S01GX03	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, temporary blurred vision or other visual disturbances, transient stinging and burning after instillation. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Spaglumic acid	R01AC05	NE	
Sparteine	C01BA04	NE	
Spirapril	C09AA11	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Spironolactone	C03DA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Stannous fluoride	A01AA04	NE	
Stanozolol	A14AA02	0	<ul style="list-style-type: none"> • No special advice
Stem cells from umbilical cord blood	B05AX04	NE	

Stepronin	R05CB11	NE	
Sterculia	A06AC03	0	• No special advice
Sterculia, combinations	A06AC53	NE	
Stiripentol	N03AX17	NE	
Stramoni preparations	R03BB03	NE	
Streptokinase	B01AD01	0	• No special advice
Streptokinase, combinations	B06AA55	NE	
Streptomycin	A07AA04	0	• No special advice
Streptomycin, combinations	A07AA54	NE	
Strontium ranelate	M05BX03	0	• No special advice
Styramate	M03BA04	NE	
Succinylsulfathiazole	A07AB04	NE	
Sucralfate	A02BX02	0	• No special advice
Sufentanil	N01AH03	NE	
Sulbentine	D01AE09	NE	
Sulbutiamine	A11DA02	0	• No special advice
Sulconazole	D01AC09	NE	
Sulfacetamide	S01AB04	NE	
Sulfadiazine	S01AB03	NE	
Sulfafena	S01AB05	NE	
Sulfafurazole	S01AB02	NE	
Sulfaguanidine	A07AB03	NE	
Sulfamerazine	D06BA06	NE	
Sulfamethizole	B05CA04 D06BA04 S01AB01	NE	
Sulfanilamide	D06BA05	0	• No special advice
Sulfasalazine	A07EC01	0	• No special advice
Sulfathiazole	D06BA02	0	• No special advice
Sulfapyridine	M04AB02	NE	
Sulfur	D10AB02	0	• No special advice
Sulfur compounds	D11AC08	0	• No special advice
Sulglycotide	A02BX08	NE	

Sulindac	M01AB02	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Suloctidil	C04AX19	NE	
Sulodexide	B01AB11	0	<ul style="list-style-type: none"> • No special advice
Sulpiride	N05AL01	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Sultiame	N03AX03	NE	
Sultopride	N05AL02	NE	
Sumatriptan	N02CC01	II	<ul style="list-style-type: none"> • Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. • Advise the patient not to drive within the first 4 hours after treatment. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Suprofen	M01AE07	NE	
Suxamethonium	M03AB01	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Suxibuzone	M01AA90	NE	

	M02AA22		
Syrosingopine and diuretics	C02LA09	NE	
T	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Tacalcitol	D05AX04	0	<ul style="list-style-type: none"> • No special advice
Tacrine	N06DA01	NE	
Tacrine	N06DA01	NE	
Tacrolimus - Intravenous administration - Oral administration - Topical use	L04AD02 D11AH01	III II 0	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine and that the medication can cause side effects that impair driving (visual and neurological disturbances). • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights). • Advise the patient not to drink alcohol when taking this medicine. This adverse effect may be enhanced if it is administered in association with alcohol.
Tafluprost	S01EE05	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Talastine	R06AB07	NE	
Talbutal	N05CA07	NE	
Talinolol	C07AB13	NE	
Tasosartan	C09CA05	NE	
Taurolidine	B05CA05	NE	
Tazarotene	D05AX05	0	<ul style="list-style-type: none"> • No special advice
Tedisamil	C01BD06	NE	
Tegaserod	A03AE02	NE	
Telmisartan	C09CA07	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Telmisartan and amlodipine	C09DB04	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair

			his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Telmisartan and diuretics	C09DA07	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Temazepam	N05CD07	III	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Temocapril	C09AA14	NE	
Tenecteplase	B01AD11	0	<ul style="list-style-type: none"> No special advice
Tenidap	M01AX23	NE	
Tenitramine	C01DA38	NE	
Tenoxicam	M01AC02	I	<ul style="list-style-type: none"> Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Terbinafine	D01AE15	0	<ul style="list-style-type: none"> No special advice
Terbinafine	D01BA02	0	<ul style="list-style-type: none"> No special advice
Terbutaline	R03AC03	0	<ul style="list-style-type: none"> No special advice
	R03CC03	0	<ul style="list-style-type: none"> No special advice
Terbutaline, combinations	R03CC53	NE	
Terfenadine	R06AX12	I	<ul style="list-style-type: none"> Inform the patient about the effects that the medicine can have on reaction time and

			<p>that the medication can cause side effects that impair driving (somnolence, insomnia, drowsiness)</p> <ul style="list-style-type: none"> • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Tertatolol	C07AA16	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Tetrabenazine	N07XX06	NE	
Tetracaine	C05AD02 D04AB06	0	<ul style="list-style-type: none"> • No special advice
Tetracaine	S01HA03	NE	
Tetracaine (anesthetic, local)	N01BA03	<p>0</p> <p>I</p> <p>II</p> <p>III</p>	<p>Categorization, labelling and information to the patient depending of the route of administration</p> <p><u>Topic administration</u> (skin, mucous)</p> <p><u>Infiltration</u> (dental anaesthesia) <u>Intrarticular, intrabursal, tendon sheath administration, etc..</u></p> <p>- Advise the patient not to drive or operate machinery until the effect of the anaesthesia and the immediate effects of surgery are passed.</p> <p><u>Ocular administration:</u></p> <p>- Advise at the patient that their sight may become blurred, and not to drive or operate machinery during the first 24 hours after using local anesthetics.</p> <p><u>Regional anaesthesia</u> (nerve-block, intravenous regional anaesthesia). <u>Spinal /Epidural</u></p> <p>- Advise the patient (and explain to caregivers), in the event an early discharge is envisaged following regional / epidural / spinal anaesthesia, not to drive or operate machinery during the first 24 hours after anaesthesia.</p>

			- Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Tetracycline	A01AB13 D06AA04	0	• No special advice
Tetracycline	S01AA09 S02AA08 S03AA02	NE	
Tetragalacturonic acid hydroxymethylester	B02BC03	NE	
Tetrazepam	M03BX07	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Tetryzoline	S01GA02	I	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause side effects including local irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased redness, blurring, punctate keratitis, lacrimation with an increase in intraocular pressure and systemic effects due to absorption (hypertension, cardiac irregularities and hyperglycaemia). Some patients may experience drowsiness. • Advise the patient that if he/she experiences these symptoms, he/she should wait until they have cleared before driving or using machinery.
Tetryzoline	R01AA06 R01AB03	NE	
Tetryzoline, combinations	S01GA52	NE	
Thebacone	R05DA10	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (drowsiness, confusion, vertigo, blurred vision) • Advise the patient not to drive for the first few days of treatment or until the next visit

			after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Thenalidine	D04AA03 R06AX03	NE	
Thenalidine, combinations	R06AX53	NE	
Theobromine	C03BD01 R03DA07	NE	
Theobromine, combinations	R03DA57	NE	
Theodrenaline	C01CA23	NE	
Theophylline - Oral administration - Parenteral administration	R03DA04	0 I	Oral: • No special advice Parenteral: • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (insomnia, confusion, anxiety, vertigo, dizziness, tremor, visual disturbances) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Theophylline and adrenergics	R03DB04	Depending on medicine in combination	• Depending on medicine in combination
Theophylline, combinations excl. psycholeptics	R03DA54	NE	
Theophylline, combinations with psycholeptics	R03DA74	NE	
Thiamine (vit B1)	A11DA01	0	• No special advice
Thiazinam	R06AD06	NE	
Thiethylperazine	R06AD03	II	• Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness)

			<ul style="list-style-type: none"> • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Thiocolchicoside	M03BX05	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Thiomersal	D08AK06	0	<ul style="list-style-type: none"> • No special advice
Thiopental	N01AF03	III	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to strictly follow the prescribed doses and the intake scheme. • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Thiopental	N05CA19	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when

			taking this medicine. <ul style="list-style-type: none"> • One time (occasional) use: inform your patient that his/her response is still reduced for a few days. Advise your patient not to drive then.
Thiopropazate	N05BA05	NE	
Thiopropazine	N05AB08	NE	
Thioridazine	N05AC02	NE	
Thonzylamine	D04AA01 R01AC06 R06AC06	NE	
Thrombin	B02BD30	0	<ul style="list-style-type: none"> • No special advice
Thrombin (with human fibrinogen)	B02BC06	0	<ul style="list-style-type: none"> • No special advice
Thrombocytes	B05AX02	NE	
Tiabendazole	D01AC06	NE	
Tiadenol	C10AX03	0	<ul style="list-style-type: none"> • No special advice
Tiagabine	N04AG06	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>Advise the patient that visual field testing should be done regularly.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Tianeptine	N06AX14	NE	
Tiapride	N05AL03	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for

			approximately 24 hours. Advise the patient not to drive then.
Tiaprofenic acid	M01AE11	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Tibezonium iodide	A01AB15	NE	
Ticlatone	D01AE08	NE	
Ticlopidine	B01AC05	0	<ul style="list-style-type: none"> • No special advice
Tidiacic arginine	A05BA07	NE	
Tiemonium iodide	A03AB17	NE	
Tiemonium iodide and analgesics	A03DA07	NE	
Tienilic acid	C03CC02	NE	
Tilactase	A09AA04	NE	
Tilidine	N02AX01	NE	
Tiludronic acid	M05BA05	0	<ul style="list-style-type: none"> • No special advice
Timepidium bromide	A03AB19	NE	
Timolol	C07AA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Timolol	S01ED01	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Timolol - amiloride - hydrochlorothiazide	C07DA06	NE	
Timolol and thiazides	C07BA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. <ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Timolol, combinations Timolol+brinzolamide (Azarga)	S01ED51	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Timolol, thiazide and other diuretics	C07DA06	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Tinzaparin	B01AB10	0	<ul style="list-style-type: none"> • No special advice
Tiocloमारol	B01AA11	NE	
Tioconazole	D01AC07	0	<ul style="list-style-type: none"> • No special advice
Tioctic acid	A16AX01	NE	
Tiopronin	R05CB12	NE	
Tiotixene	N05AF04	NE	
Tiotropium bromide	R03BB04	I	<ul style="list-style-type: none"> • Inform the patient about the effects that the medicine can have on reaction time and that the medication can cause side effects that impair driving (dizziness, blurred vision) • Advise the patient not to drive when this side effects occur and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Tioxolone	D10AB03	NE	
Tipepidine	R05DB24	NE	
Tiracizine	C01EB11	NE	
Tiratricol	D11AX08	NE	
Tirilazad	N07XX01	NE	
Tirofiban	B01AC17	0	<ul style="list-style-type: none"> • No special advice
Tiropamide	A03AC05	NE	
Tisopurine	M04AA02	NE	

Titoqualine	R06AX21	NE	
Tixocortol	A07EA05 R01AD07	NE	
Tixocortol, combinations	R01AD57	NE	
Tizanidine	M03BX02	II	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is reduced. Advise your patient not to drive then.
Tobramycin - Drops - Ointment	S01AA12	0 I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advise the patient that he/she should wait until his/her vision clears before driving or using machinery.
Tocainide	C01BB03	NE	
Tocofersolan (paediatric patients)	A11HA08	0	<ul style="list-style-type: none"> • No special advice
Tocopherol (vit E)	A11HA03	0	<ul style="list-style-type: none"> • No special advice
Tofisopam	N05BA23	NE	
Tolazamide	A10BB05	NE	
Tolazoline	C04AB02 M02AX02	NE	
Tolbutamide	A10BB03	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication

Tolcapone	N04BX01	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep attacks”. • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility (“on-off” phenomena).
Tolciclate	D01AE19	NE	
Tolfenamic acid	M01AG02	I	<ul style="list-style-type: none"> • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Tolmetin	M01AB03 M02AA21	NE	
Tolnaftate	D01AE18	0	<ul style="list-style-type: none"> • No special advice
Toloxatone	N06AG03	NE	
Tolperisone	M03BX04	NE	
Tolpropamine	D04AA12	NE	
Tolrestat	A10XA01	NE	
Tolvaptan	C03XA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Tonics	A13A	0	<ul style="list-style-type: none"> • No special advice
Topiramate	N03AX11	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician.

			<ul style="list-style-type: none"> • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication. <p>Prophylaxis of migraine headache</p> <ul style="list-style-type: none"> • Advise the patient not to drive during the first days of treatment as well as after dose increases.
Torasemide	C03CA04	0	<ul style="list-style-type: none"> • No special advice
Tosylchloramide sodium	D08AX04	NE	
Tramadol	N02AX02	III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment. • Opiate cessation can also cause behavioral changes and requires follow-up and counseling.
Tramadol, combinations	N02AX52	NE	
Tramazoline	R01AA09	0	<ul style="list-style-type: none"> • No special advice
Trandolapril	C09AA10	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Trandolapril and verapamil	C09BB10	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Tranexamic acid	B02AA02	0	<ul style="list-style-type: none"> • No special advice
Tranylcypromine	N06AF04	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as

			<p>that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.).</p> <ul style="list-style-type: none"> • Advice your patient not to drive for the first few weeks of treatment or until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advice your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advice your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Trapatepine	N04AA12	NE	
Trapidil	C01DX11	NE	
Travoprost	S01EE04	I	<ul style="list-style-type: none"> • Inform the patient that as with any ocular medication, if transient, blurred vision occurs at application. • Advice the patient that he/she should wait until his/her vision clears before driving or using machinery.
Trazodone	N06AX05	III	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advice your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advice your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advice your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Trepibutone	A03AX09	NE	
Treprostinil	B01AC21	NE	
Tretinoin	D10AD01	0	<ul style="list-style-type: none"> • No special advice
Tretinoin, combinations (with erythromycin, topical use)	D10AD51	0	<ul style="list-style-type: none"> • No special advice
Tretoquinol	R03AC09 R03CC09	NE	
Triamcinolone	A01AC01 A07EA D07AB09	0	<ul style="list-style-type: none"> • No special advice

	D07XB02 R01AD11		
Triamcinolone	R03BA06 S01BA05 C05AA12	NE	
Triamcinolone and antibiotics	D07CB01	0	• No special advice
Triamcinolone and antiinfectives	S02CA04	0	• No special advice
Triamcinolone and antiseptics	D07BB03	NE	
Triamterene	C03DB02	0	• No special advice
Triazolam	N05CD05	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time (occasional) use: inform your patient that his/her response is still reduced for approximately 24 hours. Advise your patient not to drive then.
Tribenoside	C05AX05	NE	
Tribenoside	C05CX01	0	• No special advice
Tribromometacresol	D01AE03	NE	
Trichlormethiazide	C03AA06	NE	
Trichlormethiazide and potassium	C03AB06	NE	
Trichlormethiazide and potassium-sparing agents (spironolactone)	C03EA02	NE	
Trichloroethylene	N01AB05	NE	
Triclofos	N05CM07	NE	
Triclosan	D08AE04 D09AA06	0	• No special advice
Tridihexethyl	A03AB08	NE	

Trifluoperazine	N05AA05	NE	
Trifluoperazine	N05AB06	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine. • In short-term use, inform your patient that his/her response is still reduced for approximately 24 hours. Advise the patient not to drive then.
Trifluoperidol	N05AD02	NE	
Trifluridine	S01AD02	NE	
Triflusal	B01AC18	0	<ul style="list-style-type: none"> • No special advice
Trihexyphenidyl	N04AA01	II	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment. • Inform patients that unwanted effects are seen rapidly during the dosage adjustment period. • Advise the patient (and explain to caregivers) not to drive at all if suffering from "sleep attacks". • Advise the patient (and explain to caregivers) not to drive at all if suffering from severe fluctuations in mobility ("on-off" phenomena).
Trimazosin	C02CA03	NE	
Trimebutine	A03AA05	0	<ul style="list-style-type: none"> • No special advice
Trimetazidine	C01EB15	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Trimethadione	N03AC02	NE	
Trimethyldiphenylpropylamine	A03AX30	NE	
Trimipramine	N06AA06	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive for the first few weeks of treatment or until the next

			<p>visit and to be careful in other situations, as well (e.g. operating machinery and working at heights).</p> <ul style="list-style-type: none"> • Advice your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advice your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Trioxysalen	D05AD01 D05BA01	NE	
Tripelennamine	D04AA04	0	<ul style="list-style-type: none"> • No special advice
Tripelennamine	R06AC04	NE	
Triprolidine	R06AX07	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (drowsiness, sleep disturbance) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Triticum (wheat fibre)	A06AC07	NE	
Troglitazone	A10BG01	NE	
Trolnitrate	C01DA09	NE	
Trolnitrate, combinations	C01DA59	NE	
Tromantadine	D06BB02	0	<ul style="list-style-type: none"> • No special advice
Trometamol	B05BB03	0	<ul style="list-style-type: none"> • No special advice
Trometamol (only in combination)	B05XX02	NE	
Tropenzilone and analgesics	A03DA01	NE	
Tropicamide	S01FA06	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient blurring of vision or that he/she may suffer from photophobia and that this may impair their ability to drive under certain circumstances. Complete recovery from the effects of mydriatic anticholinergics may take up to 24 hours. • Advise the patients not to drive or operate hazardous machinery until 24 hours after receiving ocular medication (recovery occurs within 24 hours) or until vision is clear.
Tropicamide, combinations	S01FA56	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient blurring of vision

			<p>or that he/she may suffer from photophobia and that this may impair their ability to drive under certain circumstances. Complete recovery from the effects of mydriatic anticholinergics may take up to 24 hours.</p> <ul style="list-style-type: none"> • Advise the patients not to drive or operate hazardous machinery until 24 hours after receiving ocular medication (recovery occurs within 24 hours) or until vision is clear.
Tropisetron	A04AA03	0	<ul style="list-style-type: none"> • No special advice
Trospium and analgesics	A03DA06	NE	
Troxerutin	C05CA04	0	<ul style="list-style-type: none"> • No special advice
Troxerutin, combinations	C05CA54	0	<ul style="list-style-type: none"> • No special advice
Troxipide	A02BX11	NE	
Trypsin	D03BA01	0	<ul style="list-style-type: none"> • No special advice
Trypsin	B06AA07	NE	
Trypsin, combinations	M09AB52	NE	
Tryptophan	N06AX02	NE	
Tuaminoheptane	R01AA11 R01AB08	NE	
Tubocurarine	M03AA02	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Tulobuterol	R03AC11	NE	
Tulobuterol	R03CC11	NE	
Tyloxapol	R05CA01	NE	
Tymazoline	R01AA13	NE	
Tyrothricin	D06AX08 R02AB02	0	<ul style="list-style-type: none"> • No special advice
Tyrothricin	S01AA05	NE	
U	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Ubidecarenone	C01EB09	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Ulobetasol	D07AC21	NE	
Undecylenic acid	D01AE04	NE	
Undecylenic acid, combinations	D01AE54	NE	
Unoprostone	S01EE02	NE	
Urapidil	C02CA06	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Urate oxidase	M04AX01	NE	
Urokinase	B01AD04	0	<ul style="list-style-type: none"> No special advice
Ursodeoxycholic acid	A05AA02	0	<ul style="list-style-type: none"> No special advice
V	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Valerian	N05CM09	I	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) Advise the patient not to drive for the first 8 hours after taking the medicine and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Valnoctamide	N05CM13	NE	
Valproic acid - Oral administration - Parenteral administration	N03AG01	II III	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p> <ul style="list-style-type: none"> Advise the patient to take the medicine as prescribed by the physician. Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so.

			<ul style="list-style-type: none"> • Advise the patient not to drink alcohol while taking this medication.
Valpromide	N03AG02	NE	
Valsartan	C09CA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Valsartan and aliskiren	C09DX02	NE	
Valsartan and amlodipine	C09DB01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Valsartan and diuretics	C09DA03	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Valsartan, amlodipine and hydrochlorothiazide	C09DX01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Vancomycin	A07AA09	NE	
Varenicline	N07BA03	I	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive during the first days of treatment and after changes in doses. • The treatment has to be used according to the recommended dose. • Advise the patient about possible effects on behavior. • Smoking cessation can also cause behavioural changes.
Various (Antiinfectives and antiseptics for local oral treatment)	A01AB11	0	<ul style="list-style-type: none"> • No special advice
Various (Antiseptics)	R02AA20	NE	

Various (Other agents for local oral treatment)	A01AD11	NE	
Various (Other nasal preparations)	R01AX10	NE	
Various (Other topical products for joint and muscular pain)	M02AX10	NE	
Various combinations (Iron in other combinations)	B03AE10	0	<ul style="list-style-type: none"> • No special advice
Various combinations (Other anti-acne preparations for topical use)	D10AX30	NE	
Vecuronium	M03AC03	III	<ul style="list-style-type: none"> • Advise the patient not to drive or operate machinery until the effects of the anaesthetic, and the immediate effects of surgery have passed. • Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after anaesthesia
Velaglucerase alfa	A16AB10	NE	
Venlafaxine	N06AX16	II	<ul style="list-style-type: none"> • Inform your patient about the effects of the medication on reaction time as well as that the medication can cause side-effects that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, etc.). • Advise your patient not to drive until the next visit and to be careful in other situations, as well (e.g. operating machinery and working at heights). • Advise your patient not to drink alcohol nor use any other psychoactive substance when taking this medication. • In case of short-term use of the medication, advise your patient not to drive because his/her driving skills are still impaired for approximately 24 hours.
Veralipride	N05AL06	NE	
Verapamil	C08DA01	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Verapamil, combinations	C08DA51	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist.

			<ul style="list-style-type: none"> • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Veratrum	C02KA01	NE	
Veratrum and diuretics	C02LK01	NE	
Verteporfin	S01LA01	III	<ul style="list-style-type: none"> • Inform the patient that this ocular medication may cause transient visual disturbances such as abnormal vision, vision decrease, or visual field defects that may interfere with their ability to drive or use machines. Patients should not drive or use machines as long as these symptoms persist. • Advise the patients not to drive or operate hazardous machinery until your vision improves.
Vidarabine	S01AD06	NE	
Vigabatrin	N03AG04	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>Advise the patient that visual field testing should be done regularly.</p> <p>General warnings:</p> <ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Vildagliptin	A10BH02	I	<ul style="list-style-type: none"> • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery), and not to drive as long as side-effects persist. • If your patient has frequent episodes or if he/she find it hard to recognise hypoglycaemia. The advisability of driving should be considered in these circumstances. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Viloxazine	N06AX09	NE	
Viminol	N02BG05	NE	
Vinbarbital	N05CA09	NE	
Vinburnine	C04AX17	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention,

			etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Vincamine	C04AX07	I	• Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Vinpocetine	N06BX18	NE	
Vinyl ether	N01AA02	NE	
Vinylbarbital	N05CA08	NE	
Virginiamycin	D06AX10	NE	
Visnadine	C04AX24	NE	
Vitamins	B05XC	0	• No special advice
Vitamin B-complex, plain	A11EA	0	• No special advice
Vitamin B-complex with vitamin C	A11EB	0	• No special advice
Vitamin B-complex with minerals	A11EC	0	• No special advice
Vitamin B-complex with anabolic steroids	A11ED	0	• No special advice
Vitamin B-complex, other combinations	A11EX	0	• No special advice
Voglibose	A10BF03	NE	
Von Willebrand factor and coagulation factor VIII in combination	B02BD06	0	• No special advice
W	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Warfarin	B01AA03	0	• No special advice
X	ATC CODE	CATEGORIZATION	INFORMATION FOR THE PATIENT

		labelling	
Xamoterol	C01CX07	NE	
Xantinol nicotinate	C04AD02	NE	
Xenon	N01AX15	NE	
Xenysalate	D11AC09	NE	
Ximelagatran	B01AE05	NE	
Xipamide	C03BA10	0	<ul style="list-style-type: none"> • No special advice
Xylometazoline	R01AA0 7	0	<ul style="list-style-type: none"> • No special advice
Xylometazoline	R01AB06 S01GA03	NE	
Xylometazoline, combinations	S01GA53	NE	
Z	ATC CODE	CATEGORIZATION labelling	INFORMATION FOR THE PATIENT
Zafirlukast	R03DC01	0	<ul style="list-style-type: none"> • No special advice
Zaleplon - after 12h	N05CF03	III I	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first 12 hours after taking the medicine and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Ziconotide	N02BG08	III	<ul style="list-style-type: none"> • Advise the patient (and explain to caregivers) not to drive until the next visit after start of treatment or after changes in dosage. • Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. • Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights). • Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Zimeldine	N06AB02	NE	

Zinc acetate	A16AX05	0	• No special advice
Zinc bandage with supplements	D09AB02	0	• No special advice
Zinc bandage without supplements	D09AB01	0	• No special advice
Zinc chloride	B05XA12	0	• No special advice
Zinc compounds	S01AX03	NE	
Zinc gluconate	A12CB02	NE	
Zinc preparations	C05AX04	0	• No special advice
Zinc products	D02AB	0	• No special advice
Zinc protein complex	A12CB03	NE	
Zinc sulphate	A12CB01	0	• No special advice
Zipeprol	R05DB15	NE	
Ziprasidone - Oral administration	N05AE04	II	Oral administration: <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
- Parenteral administration: i.m.		III	Parenteral administration <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
Zofenopril	C09AA15	I	<ul style="list-style-type: none"> • Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. • Advise your patient not to drink alcohol nor use any psychoactive substances when

			taking this medication.
Zofenopril and diuretics	C09BA15	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication.
Zoledronic acid	M05BA08	I	<ul style="list-style-type: none"> Advise your patient not to drive if he/she experiences side-effects that can impair his/her driving abilities (e.g. headache, dizziness, and not to drive as long as side-effects persist. Advise your patient not to drink alcohol nor use any psychoactive substances when taking this medication
Zolimidine	A02BX10	NE	
Zolmitriptan	N02CC03	II	<ul style="list-style-type: none"> Advise the patient not to drive during the first times, the drug is administered, until he/she knows his/her reactions. Advise the patient not to drive within the first 4 hours after treatment. Inform the patient that the medication can cause side effects that impair driving and that reaction time can also be reduced without experiencing side effects. Advise the patient also to be careful in other situations than driving (e.g. using machinery and working at heights) Advise the patient to strictly follow the prescribed doses and intake scheme. Advise the patient to avoid any alcohol or other psychoactive substances during the treatment.
Zolpidem - after 8h	N05CF02	III II	<ul style="list-style-type: none"> Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) Advise the patient not to drive for the first 8 hours after taking the medicine and also to be careful in other situations (e.g. using machinery and working at heights) Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine.
Zomepirac	M01AB04	NE	
Zonisamide	N03AX15	II	<p>Advise the patient not to drive during the first days of treatment as well as after dose increases.</p> <p>General warnings:</p>

			<ul style="list-style-type: none"> • Advise the patient to take the medicine as prescribed by the physician. • Advise the patient not to stop taking the medicine suddenly, and to inform the physician – doctor if he/she should do so. • Advise the patient not to drink alcohol while taking this medication.
Zopiclone	N05CF01	III	<ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time, that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) and that reaction time can also be reduced without experiencing side effects. • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol or use other psychoactive substances when taking this medicine. • One time use: inform your patient that his/her response is still reduced for approximately 24 hours. Advise your patient not to drive then.
Zotepine	N05AX11	NE	
Zucapsaicin	M02AB02	NE	
Zuclopenthixol - Oral administration	N05AF05	II	<p>Oral administration:</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive for the first few days of treatment or until the next visit after the start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.
- Parenteral administration: depot i.m.		III	<p>Parenteral administration</p> <ul style="list-style-type: none"> • Inform the patient about the effects of the medicine on reaction time and that the medication can cause side effects that impair driving (dizziness, drowsiness, sleepiness, blurred/double vision and reduced alertness) • Advise the patient not to drive until the next visit after start of treatment and also to be careful in other situations (e.g. using machinery and working at heights) • Advise the patient not to drink alcohol when taking this medicine.

*NE: Not evaluated. No proposed categorization and labelling because this medicine is not available in most of the DRUID WP4 countries as well as in the UK and Ireland.

*ATC: Anatomical Therapeutic Chemical (ATC) classification system.

*SmPC: Summary of Product Characteristics